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2. Abbreviations 
 
Ab  antibody 
Ag  antigen 
AIRE  autoimmune gene regulator 
APC  antigen presenting cell 
ATOC  adult thymic organ culture 
B6  C57/BL6 
BCR  B cell receptor 
BDF1  (C57/BL6 x DBA/2)F1 
BM  bone marrow 
BMT  bone marrow transplantation 
cAMP  cyclic adenosine monophosphate 
CLP  common lymphoid progenitor 
CMP  common myeloid progenitor 
DC  dendritic cell  
DL1  delta-like 1 
DN  double negative 
DNA  deoxyribonucleic acid 
DP  double positive 
FLT3  Fms-like tyrosine kinase 3 
FLT3L  FLT3L ligand 
Foxp3  forkhead box P3 
FTOC  fetal thymic organ culture 
GvHD  graft versus host disease 
HA  haemagglutinin protein of PR8 influenza virus 
HSC  hematopoietic stem cell 
IBD  inflammatory Bowel disease 
IFNγ  interferon gamma 
Ig  immunoglobulin 
IL  interleukin 
K.O.  knockout 
LN  lymph node 
LPS  lipopolysaccharide 
mAb  monoclonal antibody 
MHC  major histocompatibility complex  
N.D.  not determined 
NK  natural killer  
NKT  NK T cell  
NOD  non-obese diabetic 
NTreg  naturally occurring regulatory T cell 
NTX  non-thymectomized 
Ova  ovalbumin 
PAMP  pathogen associated molecular pattern 
pGE  promiscuous gene expression 
PRR  pattern recognition receptor 
pTα  preT α  
RA  retinoic acid  
Rag  recombination activating genes 
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RNA  ribonucleic acid 
SP  single positive 
TBI  total body irradiation 
TCD  T cell depletion 
TCR  T cell receptor 
TD  T dependant 
TEC  thymic epithelial cell 
cTEC  cortical TEC 
mTEC  medullary TEC 
TGFβ  tumor growth factor 
TI  T independant 
TLR  Toll-like receptor 
TNF  tumor necrosis factor 
Treg  regulatory T cell  
TSA  tissu-specific antigen 
TX  thymectomized 
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3. Summary 
 
In this present work, we investigated the role of dendritic cells (DC) and 
regulatory T cells (Treg) in immune tolerance as well as their potential in the 
treatment of autoimmune or graft versus host (GvH) diseases. 
 
In the first study, we show that double transgenic mice expressing influenza 
hemagglutinin (HA) under the control of the CD11c promoter and a T cell 
receptor (TCR) specific for HA develop systemic auto-immunity and die 
prematurely. In double transgenic mice, negative selection of the transgenic 
TCR expressing T cells in the thymus is practically complete, however 
significant number of activated T cells expressing the TCR clonotype can be 
found in the periphery. By breeding double transgenic mice on a rag2-
deficient background, we could demonstrate that T cells escape negative 
selection by expression of an endogenous TCR α chain.  
In clear contrast, our collaborators demonstrated that expression of HA under 
the control of the medullary thymic epithelial cell (mTEC)-specific autoimmune 
regulator (AIRE) promoter together with HA-specific TCR, results in the 
development of HA-specific naturally occurring Treg (NTreg) cells. AIRE-HA x 
TCR-HA are healthy and absolutely tolerant to HA. Altogether, these data 
strongly suggest that the outcome of antigen encounter in the thymus or the 
periphery critically depends on the identity of the antigen presenting cells.  
 
In addition, we analysed the potential of transferred HA-specific Treg cells to 
interfere with spontaneous autoimmunity in CD11c-HA x TCR-HA double 
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transgenic mice. We conclude that transfer of HA-specific Treg into newborns 
rescues double transgenic mice from early death but does not prevent or 
delay the onset of the systemic autoimmunity.  
 
In a second study, we showed that fms-like tyrosine kinase ligand (FLT3L) 
treatment, already known to increase DC number, indirectly leads to 
expansion of peripheral NTreg. The increased number of NTreg is due to 
proliferation of pre-existing NTreg, likely due to favoured interactions with the 
increased number of DC. We investigated the therapeutic potential of FLT3L 
and could show that FLT3L treatment had no effect on normal immune 
response but could prevent death induced by acute GvHD. These data re-
enforce the relevancy of FLT3L treatment in transplantation or autoimmune 
settings by its ability to increase both the number of immature tolerizing DC 
and NTreg. 
 
 
Finally, in addition to immune tolerance, we investigated the so-called 
phenomenon of auto-reconstitution already known since a long time.  
We generated bone marrow (BM) chimeras by reconstituting lethally irradiated 
C57BL/6 mice with either syngeneic rag2-deficient or CD3ε-deficient BM 
neither of which is capable of generating T cells. We show that in the absence 
of donor-derived thymopoiesis, host-derived T cells can reconstitute 35% of 
the normal T cell pool. By comparing thymectomized versus non-
thymectomized host, we show that host-derived T cells, comprised a major 
subpopulation of de novo generated, thymus-derived, polyclonal cells. Host-
5
derived thymocytes regenerated from conventional DN1-2 prothymocytes and 
their differentiation recapitulated normal thymic ontogeny. Thus, host-derived 
T cells might provide a first line of defence against infections during recovery 
from lymphopenia after BMT. This conclusion is supported by the fact that 
host-derived T cells were fully functional. 
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4. Introduction 
 
The function of the immune system is to protect individual from pathogens 
while maintaining unresponsiveness against self or non-infectious agents. 
In vertebrates, the immune system is composed of innate and acquired 
immune system, arising from bone marrow-resident haematopoietic stem cells 
(HSC). The innate immune system is one of the first lines of defence against 
pathogens; it is based on the recognition and sensing of pathogens 
associated molecular patterns (PAMP) through germline encoded pathogens 
recognition receptors (PRR) followed by activation.  
The adaptive immune system is composed of T and B cells expressing 
clonally rearranged receptors, which proliferate and fight infections upon 
antigen encounter. After pathogens clearance, most of the antigen-specific T 
and B cells undergo apoptosis while few of them enter a memory pool, this 
ensures a quicker and stronger reaction in the case of secondary infection, a 
process called memory.  
Rearrangement of T and B cell receptors is completely random and 
rearrangement products can be potentially self-reactive, therefore it is a vital 
requirement for the immune system to eliminate or control auto-reactive T and 
B cell clones in a process called tolerance. There are two different stages of 
tolerance, central tolerance defines mechanisms of clonal deletion or receptor 
editing of developing T or B cell whereas peripheral tolerance refers to the 
control of deletion auto-reactive lymphocytes that escaped central tolerance 
(Janeway, Travers, Walport & Shlomchik, Immunobiology 5th).  
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 Haematopoiesis - T cell development 
 
Like every system, the haematopoietic system relies on stem cells (HSC) with 
self-renewal capacity. HSC are located in the bone marrow and throughout 
life give rise to transient amplifying, committed and finally differentiated blood 
cells. For a long time, haematopoietic development was though to be 
dichotomic, composed of common myeloid progenitors (CMP) and common 
lymphoid progenitor (CLP) with mutually exclusive myeloid or lymphoid 
development potential 1,2. Even though such cells can be indeed isolated, it 
seems more and more clear that this model should be re-considered. There 
are increasing amount of data, which demonstrate that there is no exclusive 
decision regarding myeloid or lymphoid fate but rather a progressive loss of 
differentiation potential influenced by cell intrinsic and extrinsic stimuli 3,4.   
The first steps of haematopoiesis take place in the bone marrow and all cells 
of the blood except T cells are generated there. T cell development takes 
place in the thymus 5, an organ composed of an inner cortex and an outer 
medulla. The exact identity and homogeneity of thymus-settling cells are still 
unclear, however it is not an HSC. The essential role of notch in T versus B 
cell fate commitment in the thymus has been clearly established, it has been 
demonstrated that in absence of notch signal, B cell development occurs in 
the thymus 6, indicating that the bone marrow cell colonizing the thymus has 
still multi-potent development potential 4. This is further supported by the fact 
that early thymocytes are still able to generate NK, myeloid and dendritic cells 
4. 
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Development stages of thymocytes was first phenotypically fractionated 
according to CD4 and CD8 co-receptors expression which discriminate, from 
less to more mature, double negative cells (DN), double positive cells (DP) 
and finally CD4 or CD8 single positive cells 7. The DN population is still 
heterogeneous and was further subdivided using CD25 and CD44 defining 
the DN1 (CD44+++CD25-), DN2 (CD44+++CD25++), DN3 (CD44+CD25++) 
and DN4 (CD44lowCD25-) 8-11. 
 
Scheme 1. Comparison between T and B cell development. Rod Ceredig & 
Ton Rolink, NRI 2002 12. 
 
It is important to note that these two markers are not enough to precisely 
identify T cell precursors, for example, dendritic cells, NK and NKT cells fall in 
the DN gate according to CD4 and CD8 expression. The use of lineage 
cocktail is sometimes maid to distinguish T cell progenitors from CD4-CD8- 
differentiated non-T cells 13-15. However it is not an ideal solution because of 
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the incomplete lineage-specificity of some markers. Alternatively the level of 
c-kit might be useful to distinguish pro-T cell 11. 
Sorted DN1 and DN2 still show significant myeloid potential 4, suggesting that 
cells become fully committed at DN3 stage were V-DJ rearrangement of β 
chain begins 16. There is a need of an in-frame rearranged β chain to continue 
beyond DN3 stage, a process called β-selection; the rearranged β-chain is 
expressed together with pTα 17 and delivers a ligand-independent signal to 
allow the cells to develop further and to stop further rearrangements in a 
mechanism called β allelic exclusion 18. The rearrangement of the α chain 
takes place at DN4/DP stage 19. If this rearrangement is in-frame and 
resulting αβ TCR expressed at cell surface, cell undergo positive and 
negative selection processes. There is no allelic exclusion for α chain, 
meaning that thymocytes can potentially proceed to rearrangement at both α 
locus 20,21, a process sometimes referred as receptor editing 22.  
Positive selection ensures that TCR together with either of CD4 or CD8 co-
receptors is able to recognize the complex formed by MHC class I or II and 
self-peptide with low affinity/avidity 23-28. This is a ligand-dependant selection 
and thymocytes, which do not receive appropriate signals, undergo apoptosis 
by neglect.  
Negative selection is the mechanism by which thymocytes with a too high 
affinity/avidity for self-peptide/MHC complex are deleted from the repertoire 
and is also called T cell central tolerance 23,29. 
  
For a long time, it was hard to understand how self-specific thymocytes, which 
react against tissu-specific antigen (TSA, e.g. insulin) can be deleted in the 
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thymus. However recently it has been suggested that central tolerance toward 
TSA could be achieved via two major mechanisms. The first one is the active 
transport of TSA by dendritic cells from the periphery to the thymus or simple 
passive transport via blood circulation 30. The second one is the expression of 
TSA by thymic epithelial cells (TEC) them-selves, a mechanism known as 
promiscuous gene expression (pGE, reviewed in 31). Up to now, only one 
molecular determinant has been identified for pGE, which is the autoimmune 
regulator or AIRE protein 32,33. AIRE is mainly expressed in a minor 
subpopulation of mTEC 34 and gene deficiency in mice or human leads to 
multi-organ autoimmune disease due to partial lack of pGE. How AIRE is 
involved in tolerance toward TSA is still not completely understood. It can be 
either by deleting TSA-specific thymocytes from the repertoire via direct 
presentation of antigen by TEC or cross-presentation by dendritic cells or 
alternatively AIRE-dependent tolerance might be mediated by TSA-specific 
Treg differentiation by AIRE+mTEC 35. 
 
Thymus-dependent immune tolerance and naturally occurring 
regulatory T cells development 
 
The role of the thymus in the development of cells displaying dominant 
regulatory activity was suggested by several independent experiments in the 
1980’s. It has been demonstrated that when quail wing buds are transplanted 
on chicken embryo, the graft is rejected within 1 or 2 weeks after birth. 
However, the graft is accepted if embryonic quail thymus (still empty form 
quail haematopoietic progenitors) is co-transplanted 36. This suggests that 
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although chicken thymus is exporting cells capable of graft rejection, cells 
capable of dominant tolerance develop in grafted quail thymus. 
Similarly, in mouse it has been shown that ablation of the thymus between 
day 3 and 7 after birth results in the development of organ-specific 
autoimmune diseases 37. From these findings it was concluded that in this 
time-window a T cell subset with crucial role in self-tolerance had to be 
generated. Ten years later, the same authors could show that regulatory 
activity correlated with CD25 expression. They demonstrated that transfer of 
CD4+CD25- cells in athymic nude mice led to the induction of organ-specific 
autoimmunity. By co-transferring CD4+CD25+ cells, the induction of the 
disease could be prevented 38. Thereafter these cells were named regulatory 
T cells (Treg). 
Treg encompass a T cell population, which prevents harmful immune 
responses against self and foreign 38,39. Among Treg cells, the so-called 
naturally occurring CD4 regulatory T cells (NTreg) are the best characterized. 
This lineage is defined by the expression of the transcription factor Foxp3 40-
42. A natural mutation or conditional deletion of Foxp3 leads to lethal 
autoimmune disease, due to absence of functional NTreg, indicating their 
non-redundant role played in self tolerance and the crucial importance of 
Foxp3 43-46. NTreg develop in the thymus but it now also well accepted that 
naïve T cell can convert to NTreg in the periphery (discussed later). 
There are two different models of NTreg development in the thymus 
(discussed in 47). The first model states that NTreg development is dictated by 
TCR affinity/avidity for self-peptide/MHC class II complex, thymocyte would 
differentiate into NTreg if TCR has an affinity/avidity, which is just below 
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negative selection threshold 48. A corollary of this is that NTreg repertoire 
should be biased toward self. Most of the data supporting this hypothesis 
come from studies of double mutant mice were a transgenic TCR is 
expressed together with its ligand in the thymus. Notably, it has been shown 
that thymocyte differentiate into NTreg only when the agonist ligand is 
expressed 49. Moreover NTreg do not develop when thymocytes express a 
transgenic TCR with lower affinity for the agonist ligand, suggesting a 
threshold-hypothesis. 
In the second model, NTreg development is independent of TCR 
affinity/avidity, thymocyte would develop into the NTreg lineage either 
stochastically or upon selection on particular niche of APC. In such a model, 
TCR repertoire would not be biased toward self but rather have an 
overlapping repertoire with effectors cells. 
Large-scale repertoire analysis of effectors versus regulatory T cells TCR 
should give precious indication on mechanism of NTreg development 
however it remains challenging because of the infinite number of 
rearrangements and α/β combinations. 
Repertoire studies have been performed on mice having a fixed transgenic β 
chain. Authors reported 20% overlap between conventional and regulatory 
cell repertoire and by cloning TCR’s sampled in both population and 
addressing their self-specificity, they concluded that NTreg repertoire was 
biased toward self 50,51. The major critisms concerning these data were that 
authors performed their analysis of TCR’s with highest frequency and ignoring 
low-frequency TCR’s. To restrict the repertoire further, others have used 
transgenic mice with fixed β chain and a mini α locus 52. In this work, authors 
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carried out more detailed repertoire analysis including all TCR’s above a 
certain frequency threshold. They similarly addressed self-specificity by 
cloning TCR’s and concluded that they was NTreg were not more self-specific 
than conventional cells. It is reasonable to think that the discrepancy between 
these two studies relies in the size of the studied repertoire and whether 
NTreg are self-specific or not will certainly remains a matter of debate in the 
field.  
 
Immune response and peripheral tolerance 
 
The efficiency of the immune system relies on the sharp distinction between 
the need for an immune response or not. As already discussed, this is mainly 
achieved by the sensing of pathogens presence via expression of a battery of 
PRR 53. In normal conditions dendritic cells are poor T cell stimulators 
because they express low levels of MHC class II and co-stimulatory 
molecules. Upon ligand binding to PPR for example, dendritic cells up-
regulate MHC class II, co-stimulatory molecules and express inflammatory 
cytokines. In a mature state, they can prime T cell toward the appropriate 
response. In this regard, dendritic cells have a central role in the balance 
between immune response or not (tolerance) 54-56. 
Negative selection of self-specific thymocytes is not perfect, either due to low 
expression of self-antigen in the thymus or expression of two different TCR’s 
for example 20. Therefore there is a need for the immune system to control 
self-reactive clones in the periphery.  
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Clonal deletion. It is accepted that deletion of self-reactive clone not only 
takes place in the thymus but also in the periphery. Self-reactive T cells, 
which encounter antigen on immature DC are believed to undergo apoptosis. 
By targeting antigen expression to DC either using Ag-conjugated mAb 57 or 
by transgenesis 58, it has been shown that antigen specific mature T cells 
were deleted from the repertoire due to antigen encounter on immature DC.  
 
Regulatory T cells. As mentioned in the previous section, the term regulatory 
T cell does not refer to a homogenous T cell subset but rather regroups T cell 
subset with “immunomodulatory” functions. In this section I will only discuss 
about Foxp3+ NTreg. NTreg play an obvious non-redundant role in the 
establishment of tolerance, given the severity of Foxp3 deficient mice, 
however the mechanisms by which they control self-specific cells are less 
clear.    
Potentially NTreg could interfere with DC or T cells at all the steps of an 
immune response, namely naive T cell priming, proliferation, differentiation 
and migration. The following modes of suppressions were reported: inhibition 
of IL-2 production by conventional cells, down-regulation of co-stimulatory 
molecules or induction of tryptophan catabolism in DC, secretion of 
immunomodulatory cytokines (TGFβ, IL-10) or Perforin and granzyme and 
more recently delivery of suppressive molecules (cAMP) via gap junctions 
59,60. 
It is reasonable to hypothesize that activation of NTreg is antigen-specific 
whereas once activated NTreg can suppress in a bystander fashion 61.  
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Interestingly, published data reported the influence of the presence of PRR 
ligand in the mechanisms of suppression. Authors reported that NTreg were 
loosing their suppressive function in the presence of LPS. This was not due to 
a direct sensing by NTreg cells but rather secretion of inflammatory cytokine 
by DC upon LPS binding, which rendered conventional T cells insensitive to 
suppression 62,63. Based on these findings it was hypothesized that under 
physiological conditions conventional T cells are under constant suppression, 
irrespective of their specificity and that in the presence of pathogens 
suppression is shut down.     
Extrathymic NTreg differentiation. NTreg are known to develop in the thymus, 
however conventional cells can also convert to NTreg cells in the periphery. 
The resulting autoimmune disease after neonatal thymectomy suggests that 
such mechanisms are not sufficient to fulfil NTreg-mediated tolerance but give 
more flexibility to the immune system and more importantly clinical 
perspectives by manipulation of T cell tolerance.  
The instrumental role of dendritic cells in the conversion of naïve cell into Treg 
lineage has been demonstrated by many groups 64-67 and some molecular 
requirements of conversion mechanism have already been discovered, 
notably in oral tolerance. Two different groups independently showed that 
secondary lymphoid organs of the gut harbour a specialized subset of 
dendritic cell, which is particularly efficient in converting naïve cells to NTreg 
66,67. This process could be inhibited by addition of inhibitors of retinal 
deshydrogenases or blocking anti-TGFβ demonstrating that the conversion 
was dependent on both retinoic acid (RA) and TGFβ. The interpretation of 
these results was that RA-receptors ligation could inhibit the transcriptional 
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activity of AP-1, a dimeric transcription factor downstream of CD28 co-
stimulatory signalling and that AP-1 might interfere with stable expression of 
Foxp3 68.  
This later statement once again underlines the crucial importance of 
maturation state of DC regarding tolerance or immune response. 
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5. Thesis projects 
 
The aim of the work was to study the direct and indirect mechanisms of Treg 
and DC-mediated central and peripheral tolerance. 
 
In the first project, we addressed the role of DC in central and peripheral 
tolerance using a double transgenic system. 
The “TCR HA” mouse is a transgenic line, which expresses a T cell receptor 
specific for hemagglutinin protein (HA) of influenza virus PR8. This TCR was 
originally cloned from a T cell hybridoma derived from a T helper clone 
specific for the HA peptide 111-119 presented by I-Ed MHC class II molecules 
69. 
The “CD11c HA “ transgenic mouse expresses a membrane-bound form of 
HA under the DC-specific CD11c promoter.  
 
By crossing these two transgenic mice, we investigated: 
a) The role of DC in thymic clonal deletion and Treg differentiation. 
b) The role of DC in peripheral tolerance and autoimmunity. 
c) The therapeutic potential of Treg transfer in the treatment of systemic 
autoimmunity. 
 
 
In the second project, we proposed to study the function of dendritic cells in 
the homeostasis of NTreg cells.  
18
By using a mouse model were DC populations are either dramatically 
increased or decreased, we were able to investigate the role of DC’s in setting 
the size of the peripheral NTreg niche. 
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Abstract 
 
 
T cells escaping negative selection in the thymus can cause autoimmune 
diseases. Here we show that double transgenic mice expressing influenza 
hemagglutinin (HA) under the control of the CD11c promoter and a TCR 
specific for HA develop systemic auto-immunity.  Increased mortality, 
lymphocyte infiltrations in multiple organs, high incidence of arthritis and 
development of immune-complex glomerulonephritis a well as high titres of 
IgG autoantibodies in the serum characterize this disease. In single HA-
transgenic mice negative selection of HA-specific B cells is almost complete, 
as no HA-specific antibodies can be elicited by influenza virus stimulation. 
Although in double transgenic mice, negative selection of the transgenic TCR 
expressing T cells in the thymus is practically complete, significant numbers of 
activated T cells expressing the TCR clonotype can be found in the periphery. 
A large part of these T cells express a non-transgenic TCR α protein, 
indicating that they have escaped negative selection by expression of a 
second TCR α chain. In line with this conclusion is the finding that RAG-2 
deficient double transgenic mice have no detectable peripheral T cells and 
therefore, obviously, do not show any sign of autoimmunity. Additionally, we 
have analysed the potential of transferred HA-specific regulatory T cells to 
interfere with autoimmunity. Transfer of HA-specific Tregs into newborns 
rescued the double transgenic mice from early death but did not prevent or 
delay the onset of the systemic autoimmunity.  
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Introduction 
 
The ability to discriminate between self and non-self is a hallmark of the 
immune system and ensures that the individual is tolerant to his body’s own 
components yet able to respond to pathogens. The thymus plays a central 
role in the establishment of tolerance within the T cell compartment. Thus 
double positive thymocytes expressing a TCR with high affinity for self-
antigen are normally negatively selected. Negative selection is caused by 
bone marrow derived antigen presenting cells cross-presenting self-antigens 
that are not synthesized within the thymus (1). Moreover, medullary thymic 
epithelial cells can also cause negative selection since they may express 
gene products which are otherwise only expressed in a tissue specific 
manner (2). This promiscuous gene expression is at least to a large extent 
regulated by the transcription factor AIRE (3). The fate of thymocytes 
undergoing negative selection is either deletion (apoptosis) or functional 
inactivation (anergy). 
Although the process of negative selection in the thymus is rather efficient, T 
cells with auto-reactive receptors may escape deletion/inactivation by various 
mechanisms, such as down modulation of TCR or alterations in co-receptor 
expression levels (4-6). Nevertheless, autoimmunity caused by T cells 
escaping negative selection is rare, since their potential auto-aggression is 
further controlled by peripheral mechanisms (7).  
Nemazee (8) and Weigert (9, 10),more then a decade ago, showed that 
autoreactive B cells may be rescued from deletion by a process they named 
“receptor editing”. Thus, cross-linking of the B cell receptor on immature bone 
22
 
 
marrow B cells resulted in the up-regulation of RAG gene expression, thereby 
allowing the cells to undergo secondary gene rearrangements, especially at 
the light chain locus (11, 12). These secondary rearrangements may then 
result in the generation of B cells with a different, non-autoreactive receptor, 
which might rescue these cells from deletion. However, we have previously 
shown that such secondary light chain rearrangements also occurs when pre 
B cells are unable to form a complete BCR or when the pairing of the light 
chain with the muH chain is inefficient (13, 14). 
Recently, it was shown, that receptor editing does not necessarily result in the 
complete disapearance of the autoreactive Ig light chain (15). Thus Gerdes 
and Wabl (15) showed that a monoclonal mouse generated by transfer of 
mature B cell nuclei carried two productively rearranged Ig light chain alleles. 
Both light chains could combine with the one productively rearranged Ig 
heavy chain so as to form one non-autoreactive and unother, autoreactive 
BCR. These findings suggest that B cells expressing an autoreactive receptor 
might be rescued from negative selection by co-expressing a non-
autoreactive receptor. In fact, similar findings have been reported earlier 
using Ig transgenic mice, expressing autoreactive receptors (16). These dual 
BCR- expressing B cells might in part be responsible for the autoreactive 
antibodies found in the serum of normal individuals. Moreover a potential role 
for these B cells in the generation of “B cell” autoimmune-diseases could well 
be envisaged. 
In T cells, both the organization and the large size of the TCR α locus is very 
conducive to receptor editing. However, whether autoreactive T cells can be 
rescued from negative selection by receptor editing is not yet clear. Using a 
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very elegant TCR α “knock-in” approach, Buch et al. recently showed that 
thymocytes expressing a TCR with specificity for the HY antigen cannot be 
rescued from deletion by receptor editing (17). However, in their experimental 
system, thymocytes could only be rescued by secondary rearrangements at 
the “knock-in” allele, since the mice used for these studies carried a TCR α 
null allele on the other chromosome. Therefore, the possibility of autoreactive 
thymocytes escaping negative selection by the expression of a second TCR 
was not addressed in this study.  
Several groups have indicated that allelic exclusion at the TCR α chain locus 
is incomplete (18-20) thereby resulting in the generation of T cells that 
express two TCR’s. Indeed, during thymocyte selection, DP cells expressing 
two TCR have been shown to down-regulate expression of the potentially 
auto-reactive TCR (21). It has been suggested that dual TCR-expressing T 
cells might be involved in the development of autoimmune-diseases. In fact, it 
has been shown that T cells expressing an autoreactive receptor can be 
rescued from negative selection by the expression of a second, non-
autoreactive TCR [19]. However, these T cells are tolerant to self, but can be 
activated via their non-autoreactive TCR and thus develop into self-reactive 
effector cells. 
Here, we have analyzed the potential of dendritic cells (DC) to induce B and T 
cell autoimmunity and tolerance. Transgenic mice expressing PR8 influenza 
hemagglutinin (HA) under the control of a mouse CD11c promoter were 
generated to guide the expression of this experimental autoantigen to CD11c-
expressing DC’s. Immunization of these CD11c-HA transgenic mice with 
complete PR8 virus resulted in a strong humoral anti-viral response. 
24
 
 
However, unlike wild type mice, no antibodies to HA could be detected, 
indicating that the B cell compartment in these transgenic animals was 
tolerant to HA. In order to test the induction of T cell tolerance, CD11c-HA 
mice were crossed with mice expressing a transgenic α/β TCR specific for 
peptide 111-119 of the HA from PR8 influenza virus (22). Although negative 
selection in the thymus of these double transgenic mice is practically 
complete, all mice develop systemic autoimmune disease. This disease is 
characterized by leukocyte infiltrations in many organs, high IgG titres of 
autoantibodies, spontaneous germinal centre formation and antibodies 
depositions in the kidney. Most dramatically, over 90% of these mice die 
before 12 weeks of age. This disease appears to be caused by transgenic 
TCR expressing CD4+ T cells that have escaped negative selection through 
the concomitant expression of an endogenous TCR α gene product.   
Moreover, we investigated the therapeutic potential of transferred HA-specific 
Treg in this system. We show here that Treg transfer rescues double 
transgenic mice from premature death but neither prevents nor delays overall 
autoimmunity. 
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Results 
 
CD11c-HA mice do mount a humoral influenza-virus specific, but not 
anti-HA specific response upon immunization with PR8 virus 
Mice expressing HA under the control of the CD11c promoter were 
immunized with PR8 virus in order to test whether they were able to mount an 
IgG anti-HA response. Normal, non-transgenic BALB/c mice were used as 
positive controls. In both groups of mice the highest IgG anti-PR8 titers were 
found 21 days after immunization. However, the titer of anti-PR8 anitibody in 
CD11c-HA mice was 3-7 fold lower than in BALB/c controls (Table1). IgG 
anti-HA titers differ however much more dramatically. In immunized BALB/c 
mice, high titers of anti-HA antibodies were detectable. In fact, in BALB/c 
mice, the anti-PR8 antibody response is almost exclusively directed to HA 
(Table1). In immunized CD11c-HA mice the anti-HA titers are very low and 
comparable to those found in non-immunized mice (Table1).  Thus the anti-
PR8 response observed in CD11c-HA is directed against viral components 
other then HA. We conclude that the B cell compartment in CD11c-HA mice 
appears to be tolerant to HA. 
 
Mice    (number of animals) IgG anti-HA titer IgG anti-PR8 titer 
Control BALB/c  (12) 1/5000 – 1/7000 1/5000 – 1/7000 
CD11c-HA transgenic BALB/c  (9) 1/100 – 1/300 1/1000 – 1/2000 
 
Table 1. 
Primary IgG antibody responses in normal and HA transgenic BALB/c mice after 21 days of i.v. 
immunization with 1000 haemagglutinating units of UV-inactivated PR8 influenza virus. 
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Pathological manifestations of systemic autoimmunity in 
 (CD11c-HA x TCR-HA)F1 mice 
In order to test the potential of dendritic cells to induce T cell tolerance, 
CD11c-HA mice were crossed with mice expressing a transgenic αβ TCR 
(22) derived from a CD4 T cell clone recognizing the peptide 111-119 of PR8-
HA in the context I-Ed (23). We expected that the HA expressing DC’s could 
induce a complete arrest of all the T cells expressing the anti-HA TCR. 
Severe arrest of T cell development in the thymus was observed, however, to 
our surprise, all double transgenic mice developed a systemic autoimmune 
disease while none of the single transgenic mice showed signs of such 
disease. Thus, around 10% of double transgenic mice die before weaning 
(before 3 weeks of age). Those that survive longer, show dramatic growth 
retardation compared with single transgenic littermates. Moreover, all double 
transgenic mice suffer from diarrhea and have ruffled fur. As shown in Fig.1 
more then 90% of these mice die before 14 weeks of age. From week 5 of 
age and onwards, the vast majority of double transgenic mice show swelling 
of their paws, often starting with the front paws, suggesting the development 
of arthritis.  
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Figure 1: Premature death selectively among CD11c-HA – TCR-HA 
double transgenic mice 
The number of surviving CD11c-HA single and CD11c-HA – TCR-HA double transgenic mice 
was recorded twice a week. The groups consisted of 12 single transgenic and 38 double 
transgenic mice. 
 
 
Histological analysis revealed leukocyte infiltrations in multiple organs, 
especially those that harbor relatively large numbers of dendritic cells such as 
lung (Fig.2A), liver (Fig.2B) and heart (Fig.2C). Indirect immunofluorescence 
analysis of these sections showed that T, B and dendritic cells were present 
in these infiltrates (data not shown).  
In order to test whether the observed paw swelling in these double transgenic 
mice was the result of arthritis, cryo-sections were prepared and stained with 
safranin O. As shown in Fig. 2D, cartilage erosion and pannus formation was 
detectable in the joints of these paws. Moreover, leukocyte infiltrations were 
also observed. Thus,  (CD11c-HA x TCR-HA)F1 also spontaneously develop 
arthritis.   
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Macroscopic analysis revealed that double transgenic mice also develop 
severe splenomegaly. Thus, 300 – 400 million nucleated cells could be 
recovered from these spleens whereas spleens of single transgenic animals 
contained the normal range of 60 – 80 million nucleated cells as found in non-
transgenic BALB/c mice. FACS analysis of double transgenic spleen cells 
revealed that about one third of the nucleated cells were Ter119 positive cells 
and therefore most likely erythroid precursors, while another third were 
Gr.1/CD11b double positive cells, most likely representing myeloid precursor 
cells. Thus, the observed splenomegaly seems to be caused by 
extramedullary hematopoiesis, a phenomenon occurring in various 
hematological abnormalities, including severe autoimmunity. 
Indirect immunofluorescence analyses of spleen or lymph node sections from 
double transgenic mice showed the presence of large numbers of germinal 
centers (Fig.2E). This observation prompted us to investigate, whether the 
serum of these mice contained autoantibodies. As summarized in Fig.2G, all 
(CD11c-HA x TCR-HA)F1 mice had high titres of serum IgG anti-nuclear 
autoantibodies whereas these autoantibodies could never be detected in 
single transgenic mice.  
High titres of autoantibodies can lead to the formation of large quantities of 
immune complexes, which, in cases of inefficient clearing, may be deposited 
in the kidneys and thus result in the development of immune complex 
glomerulonephritis. In order to determine whether (CD11c-HA x TCR-HA)F1 
mice had Ig depositions in their kidneys, cryo-sections were stained with FITC 
labeled anti mouse Ig antibodies. As shown in fig. 2F, Ig deposits were 
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detectable in the glomerulæ of these double transgenic mice, suggesting that 
they also may develop glomerulonephritis. 
Overall, our findings demonstrate that (CD11c-HA x TCR-HA)F1 mice develop 
severe and systemic autoimmune disease. 
 
 
Figure 2: Lymphocytic infiltrations in lung (A), liver (B) and heart (C) and 
arthritis (D) germinal centers (E) and immune complex 
glomerulonephritis (F) in CD11c-HA – TCR-HA double transgenic mice.  
A-C Hematoxylin-eosin staining of 4 M cryosections of lung, liver and heart of a 8 week old 
CD11c-HA – TCR-HA double transgenic mouse. D Hematoxylin-eosin-safranin O staining of 
a 4 M cryosection of a decalcified front paw of a 8 week old CD11c-HA – TCR-HA double 
transgenic mouse. E indicates cartilage erosion and P indicates pannus formation. E 4 M 
cryosection of a 6 weeks old CD11c-HA – TCR-HA double transgenic mouse stained with 
anti-IgMFitc and biotinylated Peanut agglutinin revealed by TexasRed labelled streptavidin. F 
4 M cryosection of a kidney of a 10 weeks old CD11c-HA – TCR-HA double transgenic 
mouse stained with anti mouse IgFitc. G IgG antinuclear antibodies in the serum of 8 weeks 
old TCR-HA (A), CD11c-HA (B) and CD11c-HA – TCR-HA double transgenic mice (C).  Each 
symbol represents an individual mouse. The titer is defined as the highest serum dilution still 
giving a positive nuclear staining in the indirect-immunofluorescence test. 
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Activated T cells expressing the transgenic TCR are present in the 
periphery of (CD11c-HA x TCR-HA)F1 mice 
Our findings that (CD11c-HA x TCR-HA)F1 double transgenic but not the 
single transgenic mice develop systemic autoimmunity suggests that T cells 
expressing the transgenic TCR escape negative selection and become 
activated by recognizing the HA peptide on dendritic cells thereby, initiating 
disease. In order to test this hypothesis, T cell development in the thymus and 
the composition of the peripheral T cell compartment of (CD11c-HA x TCR-
HA)F1 mice were analyzed. TCR-HA single transgenic mice were used as 
controls. Our findings with the single TCR-HA transgenic mice confirm the 
previous findings of others (22), namely that in the thymus, there was strong 
positive selection of CD4 single positive cells (Fig.3A). Within the CD4SP, 
almost half of the cells express the HA-specific transgenic TCR (6.5+) 
(Fig.3C), as also previously observed (22).  
The thymi of single TCR-HA transgenic mice contained about 108 cells. In 
marked contrast, only 5 -10 x 106 thymocytes were obtained from (CD11c-HA 
x TCR-HA)F1 double transgenic mice. This low cell yield is, to a large extent, 
a reflection of effective, but not complete negative selection resulting in a 
reduced DP compartment found in these thymi (Fig.3B).  Since these mice 
suffer from severe autoimmunity, the reduced size of the DP compartment 
could also be the result of stress. 
In (CD11c-HA x TCR-HA) double transgenic F1 mice, practically all CD4SP 
thymocytes expressed the transgenic TCR α chain however cells expressing 
the complete transgenic TCR were almost completely absent (Fig.3D). This 
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finding indicates, that negative selection of TCR-HA expressing cells is very 
efficient in the thymus of (CD11c-HA x TCR-HA)F1 mice.  
In some double transgenic system, the expression of both a transgenic TCR 
together with its antigen in the thymus results in the development of antigen 
speciific Treg (24, 25). Therefore, we wondered whether the few HA-specific 
CD4SP cells were Foxp3+. However as shown in figure 3F, most of the HA-
specific CD4SP were Foxp3-, suggesting that dendritic cells induce negative 
selection rather then development of Treg cells. 
 
 
Figure 3. Central tolerance in CD11c HA x TCR HA mice. 
A & B, CD4 vs CD8 profile of TCR HA or CD11c HA x TCR HA thymocytes. C & D, 
Expression of HA-specific TCR (6.5+) within CD4SP of TCR HA or CD11c HA x TCR HA 
thymocytes. E & F, Foxp3 vs 6.5 profile of TCR HA or CD11c HA x TCR HA CD4SP 
thymocytes. 
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In order to determine whether TCR-HA expressing T cells were present in the 
periphery of (CD11c-HA x TCR-HA)F1 mice, lymph node cells were stained 
with 6.5 and CD4. As shown in Fig.4A about half of the CD4 positive lymph 
node T cells of TCR-HA single transgenic mice were 6.5 positive. Moreover, 
the majority (70%) of these were naïve T cells since they express CD62L. 
Only low numbers of these were CD62L negative (21%) and practically none 
expressed the early activation marker CD69. In marked contrast, only 10 – 
15% of lymph node CD4 cells from (CD11c-HA x TCR-HA)F1 mice were 6.5 
positive (Fig.4C). The vast majority of 6.5+ CD4 cells were CD69+ and did not 
express CD62L i.e. they were activated T cells. Additionnaly, the number of 
IFNγ-secreting CD4 T cells upon PMA/ionomycine stimulation was much 
higher in double transgenic compared to single transgenic mice (Fig 4E and 
F). Thus, although negative section of TCR-HA expressing T cells in the 
thymus of (CD11c-HA x TCR-HA)F1 mice is very efficient, some cells 
nevertheless escape this selection, and thus might be the cause of the 
systemic autoimmunity. 
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Figure 4: FACS analysis of lymph-node cells from a TCR-HA single (A & 
B) and a CD11c-HA – TCR-HA double transgenic mouse (C & D) 
Lymph-node cells from a 6 weeks old TCR-HA single (top) and a CD11c-HA – TCR-HA 
double transgenic mouse (bottom) were stained with CD4, clonotype specific 6.5, CD62L and 
CD69. A & C: CD4-6.5 staining. C & D: CD62L-CD69 staining gated on CD4+6.5+ double 
positive cells. E & F, IFNγ secretion upon PMA/ionomycine stimulation. Dot plots show IFNγ 
intracellular staining of CD4 T from spleen of TCR HA (E) or TCR HA x CD11c HA (F). 
 
TCR-HA expressing peripheral CD4 T cells in (CD11c-HA x TCR-HA)F1 
mice express an endogenous TCR α  chain  
The transgenic TCR of TCR-HA mice is formed by the combination of α- and 
β-chains containing Vβ8 and Vα4. As shown above, allelic exclusion at the 
endogenous β locus is to all intents and purposes complete in these TCR 
transgenic mice. It has however been shown, that autoreactive T cells may 
escape negative selection by the expression of a second TCR α chain [17, 
18, 19]. In order to test whether such a mechanism is also operative in our 
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(CD11c-HA x TCR-HA) F1 mice, we stained lymph node cells with CD4, 6.5 
and an antibody specific for the non-transgenic Vα2 family, expressed by 10-
15% of T cells in normal Balb/c mice. A representative example of such a 
staining is shown in Fig.5. Thus, about 20% of the CD4, 6.5 double positive T 
cells in (CD11c-HA x TCR-HA)F1 mice expressed a TCR α chain using the 
Vα2 family member. This finding demonstrates that in addition to the Vα4 
transgene, some 6.5+ T cells express on their surface a second, endogenous, 
TCR α chain. Note also the slightly reduced 6.5 expression on the Vα2+ cells 
(Fig 5, upper right quandrant). Therefore, autoreactive T cells in (CD11c-HA x 
TCR-HA)F1 mice might indeed escape negative selection by expressing a 
second TCR α chain. 
 
Figure 5: CD4+6.5+ double positive lymph-node cells from CD11c-HA – 
TCR-HA double transgenic mice do express a second TCR  chain  
Lymph-node cells from 6 weeks old CD11c-HA – TCR-HA double transgenic mouse were 
stained with CD4, clonotype specific 6.5 and clontype unrelated anti Vα2. The dot plot 
represents the 6.5 – Vα2 staining on gated CD4 positive cells. 
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No signs of systemic autoimmunity in (CD11c-HA x TCR-HA) 
rearrangement deficient, RAG2-/- F1 mice  
To test the hypothesis that the observed systemic autoimmunity in (CD11c-
HA x TCR-HA)F1 mice might be caused by autoreactive T cells that have 
used a second TCR  αchain to escape negative selection, we generated 
(CD11c-HA x TCR-HA)F1 mice on a RAG2 deficient background.  
In marked contrast to (CD11c-HA x TCR-HA)F1 mice on a RAG2 proficient 
background, none of these RAG2 deficient, double transgenic mice 
developed diarrhea, nor did they develop paw swelling. Moreover, over 95% 
of the double transgenic mice on a RAG2 deficient background survived for 
more then 3 months. Also, histological analysis of organs from RAG2 
deficient double transgenic mice showed no signs of lymphocyte infiltrations 
in lung, liver or heart. In conclusion, RAG2 deficient (CD11c-HA x TCR-HA)F1 
mice do not develop systemic autoimmunity. 
In order to test whether the absence of disease correlated with complete 
negative selection in the thymus and no T cells in the periphery ™FACS 
analysis was performed. TCR-HA single transgenic mice on a RAG2 deficient 
background were used as controls. The recovery of thymocytes from both 
types of mice was 50 – 70 x106. However, CD4, CD8 and 6.5 staining 
revealed a marked phenotypic difference between them. Thus, a strong 
positive selection of CD4 single positive thymocytes was found in RAG2 
deficient TCR-HA single transgenic mice (Fig.6A). Moreover, CD4 dull cells 
(representing CD4/CD8 double positive cells) expressed low to intermediate 
levels of 6.5 whereas CD4 high cells (representing CD4 single positive cells) 
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expressed high levels of 6.5 (Fig.6B). In the thymus of RAG2 deficient 
(CD11c-HA x TCR-HA)F1 mice, only double negative and double positive 
thymocytes were found (Fig.6C). Moreover, low level expression of 6.5 was 
observed on double negative cells whereas CD4 cells did not express 6.5 
(Fig.6D). Thus, negative selection of TCR-HA T cells is complete in the 
thymus of RAG2 deficient (CD11c-HA x TCR-HA)F1 mice. Moreover, no TCR-
HA T cells were found in the periphery of these mice (Fig.6F), while about 
15% of the cells in the spleen of RAG2 deficient TCR-HA single transgenic 
mice expressed both CD4 and 6.5 (Fig.6E). From these findings, we conclude 
that the systemic autoimmunity in RAG2 proficient (CD11c-HA x TCR-HA)F1 
mice is caused by autoreactive T cells, which have escaped negative 
selection through the concomitant expression of a second TCR αchain.  
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Figure 6: FACS analysis of thymus and spleen of TCR-HA single and 
CD11c-HA – TCR-HA double transgenic mouse on a RAG2 deficient 
background. 
Thymocytes derived from 6 weeks old RAG2 deficient TCR-HA single transgenic (A & B) and 
CD11c-HA – TCR-HA double transgenic mice (C & D) were stained with CD4, CD8 and 
clonotype specific 6.5. A, C: CD4-CD8 staining. B, D: CD4-6.5 staining. Spleen cells derived 
from 6 weeks old RAG2 deficient TCR-HA single transgenic (E) and CD11c-HA – TCR-HA 
double transgenic mice (F) were stained with CD4 and 6.5. 
 
Partial rescue from CD11c HA x TCR HA mice premature death but not 
autoimmunity by transfer of HA specific Treg from Ig  HA x TCR HA 
We hypothesize that if systemic autoimmunity in CD11c-HA x TCR-HA was 
due to lack of peripheral T cell tolerance toward HA, disease could be treated 
by transfer of HA-speficic regulatory T cells. In Igκ-HA transgenic mice, HA 
expression is driven by kappa light chain promoter (26). These mice have 
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originally been generated to target HA expression to B cells but it appeared 
that HA expression was broader than expected due to promoter leakiness 
(27). At mRNA level, expression was reported in B cells as well as cTEC and 
mTEC. Igk-HA x TCR-HA double mice are tolerant to HA and do not suffer 
from autoimmune disease. In addition, it has been demonstrated that sorted 
CD4+6.5+ cells from Igκ-HA x TCR-HA display in vitro and in vivo HA-specific 
regulatory activity.  
We wondered whether transfer of sorted cells would ameliorate the outcome 
of spontaneous autoimmune disease in CD11c-HA x TCR-HA mice. We 
reasoned that injecting cells as early as possible would increase the chances 
to establish tolerance and we therefore decided to inject newborn CD11c-HA 
x TCR-HA mice. As control, we injected either effector HA-specific CD4 T 
cells from TCR-HA mice or CD25+ CD4+ Treg from WT mice with an 
expected polyclonal repertoire. As shown in figure 7A, only injection of HA-
specific Treg cells could partially prevent premature death of CD11c-HA x 
TCR-HA animals, whereas injection of effector HA-specific T cells were 
actually accelerating death rate. However, transfer of HA-specific Treg could 
not prevent autoimmune symptoms, treated CD11c-HA x TCR-HA mice still 
suffered from arthritis and had similar auto-antibody titres as non-treated 
animals (Fig 7B). In contrast, injecting HA-specific Treg cells 3 weeks after 
birth of CD11c-HA x TCR-HA mice could not prevent premature death of the 
mice suggesting that they inefficiently improve outcome of ongoing disease 
(data not shown). In conclusion, transfer of HA-specific Treg in CD11c HA x 
TCR HA animals improved autoimmune symptoms responsible for early death 
but did not prevent overall auto-immunity.  
39
 
 
  
Figure 7: Treatment of CD11c HA x TCR HA mice. 
A, Newborn CD11c HA x TCR HA mice were injected with either HA-specific cells from Igk 
HA x TCR HA mice (75’000-370’000 sorted cells), HA-specific cells from TCR HA mice 
(200’000-300’000 sorted cells) or CD4+CD25+ from BalB/c WT mice (75’000-120’000 sorted 
cells). The number of surviving CD11c-HA single and CD11c-HA – TCR-HA double 
transgenic mice was recorded twice a week.B, Autoantibody titres in TCR HA, CD11c HA x 
TCR HA control or treated with HA-specific Treg. (The titer is defined as the highest serum 
dilution still giving a positive nuclear staining in the indirect-immunofluorescence test). 
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Discussion 
 
In this paper we described a spontaneous, lethal systemic autoimmune 
disease which develops in TCR-HA transgenic mice when expression of the 
HA antigen was controlled by the CD11c promoter. The disease could be 
avoided when the expression of a second, endogenously rearranged TCR 
α chain cannot occur in RAG-deficient (CD11c-HA x TCR-HA) F1 mice. 
Therefore, TCR-HA expressing T cells that escaped negative selection in the 
thymus by the expression of second TCR α chain seems to cause this 
disease. In WT animals, it was estimated that about 30% of T cells could 
express two different TCR’s, due to rearrangement of two α chains and the 
absence of α allelic exclusion (18). Some of these cells might escape 
negative selection by similar mechanisms described here and could 
potentially lead to autoimmunity, e.g. by bystander activation through the non 
self-reactive TCR. However, there are controversies among data regarding 
this issue (28) and systematic usage of TCR transgenic mice is a clear 
limitation for the relevancy of these data under physiologic conditions. 
 
We discussed the reasons why, despite efficient negative selection HA-
specific T cells were present in the periphery, however the way these cells get 
activated remains obscure and we can only speculate about this 
“spontaneous activation”. 
Currently it is believed that T cells need three different signals to get activated 
i) a strong TCR signal, which ensures specificity of the response ii) co-
stimulatory signals delivered by mature APC, which ensures the need of an 
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immune response in presence of pathogens or endogenous “danger” signals 
and iii) signals priming naïve cells to Th1, Th2 or Th17 phenotype (29). When 
T cells receive only a strong TCR stimulation without any others signals, they 
are believed to undergo apoptosis (30, 31). Among others, this mechanism 
ensures that self-reactive T cells that escaped negative selection will not 
initiate autoimmune response when antigen is encountered in the periphery. 
There are numbers of publications supporting this model, most of them using 
transgenic TCR mice. We have no clear experimental evidences to explain 
why HA-specific T cells get activated in CD11c-HA x TCR-HA mice whereas T 
cells are deleted in similar conditions in other systems however we can come 
with several hypothesises.  
Firstly, it might be due to spontaneous or abnormal activation of DC by 
expression of HA itself. Influenza viruses are known to be mitogenic with high 
variations between strains and it has also been shown that purified HA protein 
have mitogenic potential as well (32, 33). Further more, it has been 
demonstrated that HA from measles virus was activating TLR2 signalling (34), 
therefore it might be possible that HA from PR8 is inducing direct DC 
maturation as a TLR ligand although we do not have any data supporting this 
hypothesis.  
Secondly, it might be due to the pathogen status of the mice, which can also 
be a cause of dendritic maturation. Mice were bred in specific-pathogen-free 
conditions and not germ-free conditions and therefore occasional minor local 
infections could induce maturation of DC. No matter the cause of DC 
maturation, in this system autoimmune response might be very quickly 
initiated for two reasons i) as discussed before, every CD4 T cells can 
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potentially express HA-specific TCR at the cell surface and ii) once activated, 
T cells express CD40L and can activate more DC upon antigen encounter 
(35), creating an activation circle (DC activate T cells, T cells activate DC via 
CD40 and so on). 
Thirdly, we cannot exclude that the CD11c transgene inserted in a gene or a 
regulatory element disturbing expression of gene(s) playing a role in the 
maintenance of immunological tolerance. However, it seems rather unlikely 
because of the absence of a phenotype in CD11c-HA single transgenic mice. 
Fourthly, the anti-HA immune response might be due to lack of control by HA-
specific Treg cells.  We have indeed demonstrated that HA-specific Treg are 
found in very low percentages in CD11c-HA x TCR-HA mice. Therefore in the 
absence of sufficient number of HA-specific Treg, effector cells could get 
activated and induce autoimmune response. 
 
There is currently considerable research ongoing on Treg manipulation to 
cure autoimmune disease and allergies, as well as to induce transplantation 
tolerance. We have investigated here their potential to establish peripheral 
tolerance in transfer settings. Our data demonstrate that injection of HA-
specific Treg into CD11c-HA x TCR-HA mice shortly after birth was improving 
their survival but could not prevent autoimmunity. Unfortunately we were not 
able to monitor injected cells proliferation, migration and survival because we 
were lacking congenic marker to distinguish donor from host cells. It was 
therefore not possible to dissect mechanism of Treg mediated protection.  
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However, it seems likely that premature death of double transgenic mice is 
due to IBD. Therefore we favour the hypothesis that transferred Treg 
ameliorate IBD symptoms as it was shown by others already (36).  
 
Although Treg treatment improved survival of CD11c-HA x TCR-HA mice it is 
important to underline that it failed to establish peripheral tolerance. The fact 
that the thymus of CD11c-HA x TCR-HA mice constantly produces auto-
reactive T cells whereas we performed a single Treg injection let us think that 
there might be an imbalanced ratio between effector and regulatory cells, 
which could explain the persistence of autoimmune symptoms. We did not 
perform repetitive injections of Treg in order to keep a fair effector/regulatory 
ratio, however the therapeutic success of such a treatment is questionable. 
It seems that when thymus is chronically exporting self-reactive T cells, the 
resulting autoimmunity is very hard to control. E.g. AIRE deficient mice suffer 
from multiple signs of autoimmunity likely due to defect in negative selection 
of tissue-specific antigens (TSA) reactive T cells and maybe absence of TSA-
specific Treg. Grafting AIRE deficient thymus on nude mouse recapitulates 
AIRE deficient phenotype. It has been shown that even co-transplantation of 4 
wild-type thymi, which are expected to produce a “normal” Treg compartment, 
cannot completely rescue autoimmunity (37). In other words, it suggests that 
Treg fail to control self-reactive T cells when they are constantly produced by 
the thymus. We can postulate, that Treg compartment can only control a 
limited frequency of self-reactive T cells above which autoimmunity can 
manifest. Not tolerant is dominant in this experimental setting. 
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Overall it seems that there are not much backup in mechanisms controlling 
tolerance. Example of single mutations leading to autoimmunity are not rare, 
examples are listed in table 2. This suggests that when a mechanism of 
central or peripheral tolerance is defective, immune system has difficulties to 
cope with it and in the worse cases it leads to death of the mice.  
It also illustrates the difficulty to keep the balance between tolerance and 
immune response. 
 
 
Gene 
 
Human disease 
Mouse mutant 
 or  
knockout 
 
Mechenism of autoimmunity 
 
 
AIRE 
 
 
APS-1 
 
 
K.O. 
 
Decreased expression of TSA. 
Defect in negative selection of 
TSA specific T cells 
 
CTLA4 
Association with 
Graves’ disease type 
1 diabetes and others 
 
K.O. 
Failure of T cell anergy and 
reduced activation threshold of 
self-reactive T cells 
FOXP3 IPEX (scurfy) K.O. and 
mutations 
Decreased generation of 
regulatorgy T cells 
FAS, FASL ALPS Lpr/lpr; gld/gld 
mutants 
Failure of apoptotic death of self-
reactive B and T cells 
C4 
complement 
protein 
 
Associated with SLE 
 
K.O. 
Defective clearance of immune 
complexes and possible failure of 
B cell tolrance 
 
Table 2. Siimple genetic traits linked with autimmunity. Adapated from (38). 
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Materials and methods 
 
Mice 
BALB/c, BALB/c RAG2 deficient, Igk HA BALB/c (26) 
 mice and BALB/c mice expressing a transgenic a b TCR specific for peptide 
111 – 119 of HA (22) were bred under SPF conditions in our animal unit. For 
the generation of transgenic mice expressing HA under control of the CD11c 
promoter, the complete coding region of the HA gene of influenza virus 
A/PR8/34 was PCR amplified from the cDNA clone pGEM-4-HA  (kindly 
provided by Dr. A. Caton, Wistar Institute, Philadelphia, PA). The HA PCR 
product was inserted as a blunt-end product into the EcoRI site of rabbit b-
globin gene of the CD11c-promoter vector as previously described  (39), (the 
CD11c-promoter vector was kindly provided by Dr. T.Brocker, University of 
Munich, Germany). The plasmid DNA was linearized by XhoI and NotI 
digestion and injected into fertilized oozytes from BALB/c mice.  HA-
transgenic mice were selected by PCR analysis using mouse tail DNA as a 
template and the following HA-specific primers: 5’-
TCCCTCAGCTCCTCATAGTC-3’ and 5’- GAAAGGACTCTGGATTTCCATG-
3’. Of the nine different founder mice, five expressed the HA transgene as 
determined by RT-PCR and by FACS analysis using a rat anti HA monoclonal 
antibody (kindly provided by Dr. A. Caton, Wistar Institute, Philadelphia, PA). 
All 5 founder mice expressed the HA in a CD11c specific manner. The 
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CD11c-HA founder mouse 22 was used in the experiments described in this 
manuscript. 
 
Antibodies and flow cytometric analysis 
FITC-, PE-, APC- or biotin-conjugated mAb specific for CD4 (L3T4), 
CD8a (53-6.7), CD69, CD62L, Vβ8 (F23.1) and Vα2 (B20.1) were purchased 
from BD Biosciences (Allschwil, Switzerland). Streptavidin, conjugated to PE, 
APC or PE/Cy7 were also purchased from BD Biosiences. Anti-Foxp3 (FJK-
16s) and anti-IFNg (XMG1.2) were purchased from ebioscience. The rat anti-
TCR-HA clonotype specific mAb 6.5  (22) was purified from the hybridoma 
supernatant and labeled with biotin in our lab by standard methods. Flow 
cytometry was performed using a TMFACS Calibur (BD Biosiences) and data 
were analyzed using the TMCell Quest Pro Software (BD Biosiences).    
 
Histology    
Fresh organs were embedded in OCT-compound (Sakura, Zoetermeer, NL), 
snap frozen and 5mm sections were cut with a cryostat. Sections were air 
dried for 60 min and then stained with hematoxylin-eosin according to 
standard methods. To determine bone/cartilage destruction, paws were fixed 
for 24hrs in 4% paraformaldehyde.  After washing for 60 min in PBS and 
subsequently 60 min H2O the specimens were decalcified for 3 – 5 days in 
water containing 0.15M EDTA and 70mM HCL. After extensive washing in 
water the paws were embedded in OCT-compound, snap frozen and 5-8mm 
cryosections were prepared. Cryosections were stained with Safranin O 
according to standard methods. 
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Immunofluorescence and detection of autoantibodies 
Cryostat sections from fresh organs prepared as described above were fixed 
in acetone for 10 min and then air dried for 60 min. To determine the 
presence of germinal centers in spleen, sections were incubated with anti-IgM 
FITC  (mAb M41) and biotinylated peanut agglutinin (PNA) (Vector, 
Burlingame, CA) for 30 min. After 20 min washing in PBS, PNA binding was 
revealed with texas red conjugated strepavidin (SouthernBiotech, 
Birmingham, AL). To determine Ig deposits in kidneys, sections were 
incubated with FITC labeled goat anti-mouse Ig (Jackson Immunoresearch, 
Milan Analytica, La Roche, CH). IgG autoantibodies against nuclear antigens 
were detected by an indirect immunofluorescence technique, using a FITC 
labeled goat ant-mouse IgG (Jackson Immunoresearch, Milan Analytica, La 
Roche, CH); cryosections of kidneys from Rag2 deficient mice were used as 
substrate. 
 
Immunizations and detection of anti-PR8 and anti-HA antibodies  
Mice were immunized i.v. with UV-inactivated inluenza virus PR8 at a dose of 
1000 HAU. Thereafter mice were bled at regular intervals and IgG anti-PR8 
antibodies determined by ELISA as previously described (26). IgG anti-HA 
antibodies were detected by FACS analyses using HA-transfected cell lines 
as a substrate and FITC-conjugated goat-anti-mouse IgG for detection. For 
both assays, titers of antibodies are expressed as the highest dilution 
resulting in readings twice over background. 
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PMA/ionomycine stimulation 
Total lymphocytes were stimulated during 2h in Ionomycine (sigma, I9657) 
1µg/ml and Phorbol-12-Myristate-13-acetate (PMA) 5ng/ml at 37°C. After 2h, 
Brefeldin A (Calbiochem, 524400) was added at 10µg/ml final concentration 
and cells were incubated 2 more hours. Finally cells were harvested and 
stained by standard intracellular staining procedure ( ). 
 
Treg treatment 
Treg cells were sorted as described using a FACS ARIA and injected in the 
liver of newborn mice. 
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Selection of Foxp3+ regulatory T cells specific for self
antigen expressed and presented by Aire+ medullary
thymic epithelial cells
Katharina Aschenbrenner1, Louise M D’Cruz1,3, Elisabeth H Vollmann1,3, Maria Hinterberger1, Jan Emmerich1,
Lee Kim Swee2, Antonius Rolink2 & Ludger Klein1
The parameters specifying whether autoreactive CD4+ thymocytes are deleted (recessive tolerance) or differentiate into
regulatory T cells (dominant tolerance) remain unresolved. Dendritic cells directly delete thymocytes, partly through cross-
presentation of peripheral antigens ‘promiscuously’ expressed in medullary thymic epithelial cells (mTECs) positive for the
autoimmune regulator Aire. It is unclear if and how mTECs themselves act as antigen-presenting cells during tolerance
induction. Here we found that an absence of major histocompatibility class II molecules on mTECs resulted in fewer polyclonal
regulatory T cells. Furthermore, targeting of a model antigen to Aire+ mTECs led to the generation of specific regulatory T cells
independently of antigen transfer to dendritic cells. Thus, ‘routing’ of mTEC-derived self antigens may determine whether
specific thymocytes are deleted or enter the regulatory T cell lineage.
The idea that the thymic epithelium is critical for the induction of
dominant tolerance dates back to the 1980s1. The cell type mediating
tolerance in those studies remained elusive; however, follow-up studies
suggested a subset of CD4+ T cells2. It is now widely accepted that
‘natural’ Foxp3+CD25+ regulatory T cells (Treg cells), the best
characterized mediators of dominant tolerance so far, originate in
the thymus3–5.
Early studies suggesting a thymic origin of Treg cells
6,7 have been
complemented by T cell receptor (TCR) sequence analyses demon-
strating a considerable overlap between thymic and peripheral Treg cell
repertoires8,9. Findings in mice expressing transgenes encoding both
TCR and cognate antigen have bolstered this idea by establishing that
expression of self antigen in the thymic epithelium can be sufficient
for the generation of antigen-specific Treg cells. Those findings were
often (incorrectly) interpreted to mean that recognition of the
respective antigen in the context of major histocompatibility complex
(MHC) class II on epithelial cells induces Treg cell differentiation.
The antigen-presenting cell (APC) that ultimately displayed thymic
epithelium–derived antigen was not identified in any of the models.
Furthermore, most of those studies did not allow for a distinction
between cortical thymic epithelial cells (cTECs) and medullary thymic
epithelial cells (mTECs) as a source of antigen10–15, and only one
report suggested involvement of exclusively mTEC-derived antigen16.
Open issues pertaining to the exact nature of the antigen-expressing
and/or antigen-presenting cells involved in Treg cell development are
intimately related to the issue of whether specification of Treg cells is an
early (cortical) or late (medullary) event during thymocyte develop-
ment. Studies of polyclonal T cell repertoires have yielded conflicting
results, some favoring a cortical specification17 and others favoring a
medullary specification18 of Treg cell fate.
A separate line of experiments has firmly established that mTECs
contribute to T cell tolerance by ‘promiscuously’ expressing a wide
range of otherwise tissue-specific antigens19,20. Mutations in the gene
encoding the autoimmune regulator Aire, which in epithelial com-
partments of the thymus is expressed exclusively in the medulla,
perturb ‘promiscuous’ expression of tissue-specific antigens and cause
autoimmune polyendocrine syndrome in humans and general auto-
immunity in mice21. Evidence suggests that tissue-specific antigens
expressed in mTECs contribute to central tolerance in an essential way
by inducing recessive tolerance (such as clonal deletion of autoreactive
thymocytes)22,23, whereas their eventual function in the induction of
dominant tolerance remains speculative. Very limited information is
available about the type of APC that ultimately presents mTEC-
derived antigens to trigger deletion of antigen-specific thymocytes.
The importance of TEC-derived self antigens for the induction of
both dominant and recessive modes of central tolerance is undis-
puted24–26. However, it remains unclear whether thymocyte deletion
or the generation of Treg cells resulting from antigen expression in
mTECs or TECs in general is triggered in a TEC-autonomous way.
This issue is of particular importance because intercellular transfer
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of self antigens from epithelial to hematopoietic cells in the thymic
microenvironment is a well documented phenomenon27,28. In fact,
two reports have suggested a central function for thymic dendritic cells
(DCs) in the establishment of both recessive and dominant CD4+ T
cell tolerance. First, deletion of TCR-transgenic CD4+ thymocytes in
response to a model antigen expressed in mTECs requires antigen
transfer to hematopoietic cells, most likely DCs29. Second, in vitro
evidence suggests that thymic DCs conditioned with thymic stromal
lymphopoietin may promote the generation of Treg cells in the human
thymus30. Those findings collectively sparked the idea that thymic
DCs may serve a dual, possibly mandatory, function in central CD4+ T
cell tolerance by inducing negative selection as well as Treg cell
generation; in contrast TECs may merely serve as an antigen reservoir.
The ensuing mode of tolerance might then be dictated by the
maturation state of the DCs31. In mechanistic terms, this model
may offer a ‘missing link’ between thymic induction of ‘natural’ Treg
cells and peripheral, new generation of ‘induced’ Treg cells through
subimmunogenic delivery of cognate antigen32,33. An alternative view
would hold that quantitative and/or qualitative features of intrathymic
antigen recognition in the context of DCs versus TECs would favor
deletion versus Treg cell differentiation, respectively. We began our
study here to clarify the functions of epithelial versus hematopoietic
antigen presentation during the generation of Treg cells in mouse
thymus. Furthermore, we aimed to explore the potential contribution
of mTECs to Treg cell development, with particular emphasis on their
potential functions as antigen reservoirs and/or as true APCs.
RESULTS
Selection of polyclonal Treg cells by mTECs
To test whether MHC class II expressed exclusively on TECs was
sufficient for the selection of polyclonal Treg cells, we generated
chimeric mice in which only TECs expressed MHC class II. To do
this, we made use of the fact that reaggregate thymic organ cultures
(RTOCs)34 form a normal thymic microenvironment after engraft-
ment under the kidney capsule35. Experiments addressing this with
fetal thymic lobes at embryonic day 10 (E10) or treated with
deoxyguanosine have been called into question because of the formal
caveat that minute amounts of MHC class II–positive hematopoietic
cells may have persisted in the graft31. To rigorously prevent contam-
ination with ‘carryover’ hematopoietic cells, we prepared RTOCs from
cell suspensions of MHC class II–positive E14 thymi after strin-
gently depleting them of CD45+ hematopoietic cells and transplanted
the RTOCs into MHC class II–sufficient C57BL/6 recipient
mice (WT-WT) or MHC class II–deficient C57BL/6 recipient mice
(WT-H2-Ab1–/–). Analysis of thymocyte subsets in the grafts after
8–10 weeks showed that selection of Foxp3+CD25+ Treg cells occurred
efficiently in WT-H2-Ab1–/– and WT-WT chimeras (Fig. 1). As
these grafts did not differ in their overall cellularity, the somewhat lower
frequency of Foxp3+CD25+ Tregs among CD4
+ single-positive (SP) cells
in WT-H2-Ab1–/– grafts was more than compensated for in terms of
absolute numbers by the much greater frequency of CD4+ SP cells in
the absence of MHC class II on hematopoietic cells (Fig. 1a). The
extent to which CD4+ SP numbers were higher was in good agreement
with estimates that normally about 60% of CD4+ SP cells are negatively
selected after encounter with self antigen on thymic DCs36.
Next we sought to delineate the contribution of cortical versus
medullary TECs to the generation of polyclonal Foxp3+ Treg cells. We
hypothesized that elimination of MHC class II expression on medul-
lary TECs would demonstrate involvement of mTECs in Treg cell
selection. To test this idea, we again grafted RTOCs into H2-Ab1–/–
mice. This time, the RTOCs contained a 1:1 mixture of CD45– cells
from wild-type and H2-Ab1–/– E14 thymi. Flow cytometry of these
mixed RTOCs at 8–10 weeks after grafting confirmed that bulk T cell
development was efficiently supported and histological examination
confirmed that the grafts were properly compartmentalized into
cortical and medullary regions (data not shown). Notably, whereas
the cortex contained a random mixture of MHC class II–positive and
MHC class II–negative input cells, some medullary ‘islands’ formed
that, because medullary regions arise clonally from individual pre-
cursors35, were composed of either MHC class II–positive or MHC
class II–negative cells (Fig. 2a and Supplementary Fig. 1 online). An
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Figure 2 In situ detection of Foxp3+ cells in MHC class II–positive or MHC
class II–negative medullary ‘islands’ in mixed RTOCs. (a) Staining of serial
cryosections through entire grafts for medullary areas (MTS10) and MHC
class II to identify MHC class II–positive (MHC+) or MHC class II–negative
(MHC–) medullary regions. Top row, MTS10 (green) and MHC class II (red);
bottom row, MTS10 (green) and Foxp3 (red) in an adjacent section. Scale
bars, 50 mm. (b) Quantification of Foxp3+ cells in medullary ‘islands’; two to
four exclusively MHC class II–positive or MHC class II–negative medullary
regions could be identified in each of a total of three mixed RTOCs.
Figure 1 Selection of polyclonal Foxp3+CD25+ Treg cells by MHC class II
expressed exclusively on thymic epithelium. RTOCs were generated from
CD45– thymic stromal cells prepared from E14 MHC class II–positive
(wild-type) donors. After 48 h of in vitro culture, RTOCs were grafted under
the kidney capsules of wild-type or MHC class II–deficient (H2-Ab1–/–)
recipients; 8–10 weeks later, single-cell suspensions of grafts were
stained with antibodies specific for CD4, CD8, CD25 and intracellular
Foxp3. (a) Thymocyte subsets in grafts (donors and hosts, above plots) and
in thymi of C57BL/6 mice (B6). Wild-type host, n ¼ 3; H2-Ab1–/– host,
n ¼ 6; C57BL/6 mice, n ¼ 5. (b) Expression of surface CD25 and
intracellular Foxp3 on gated CD4+ SP thymocytes. Numbers above outlined
areas indicate percent (± s.d.) CD4+ SP cells (a) or Foxp3+CD25+ cells (b).
Data are representative of two independent experiments.
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experimental limitation of our approach was that the clonally derived
‘spheres’ expanded over time and thus ultimately became confluent; a
considerable fraction of medullae consisted of a ‘patchwork’ of MHC
class II–positive and MHC class II–negative regions (data not shown).
Therefore, we used serial sectioning to identify medullary regions that
were composed exclusively of either MHC class II–positive or MHC
class II–negative cells. We then quantified Foxp3+ cells per volume unit
in MHC class II–positive or MHC class II–negative medullae
(Fig. 2b) and found significantly more Foxp3+ Treg cells in MHC
class II–positive medullary regions. These results collectively supported
the idea that interactions of developing thymocytes with MHC class II
on mTECs are critical for the development of polyclonal Treg cells.
Antigen-specific differentiation of Treg cells
The function of specific antigen remains unclear when studying
polyclonal Treg cells. To address the function of mTEC-derived self
antigen in the generation of antigen-specific Treg cells, we exploited the
specific expression pattern of Aire to produce a model antigen
exclusively in mTECs. We generated a bacterial artificial chromosome
transgenic construct containing 50 kilobases of 5¢ region and
122 kilobases of 3¢ region flanking Aire, in which we replaced the
Aire start codon with an open reading frame encoding a fusion protein
of influenza hemagglutinin (HA) and green fluorescent protein (GFP).
Preliminary characterization of two transgenic founder lines indicated
they had identical phenotypes, and we chose one founder line (called
‘AIRE-HA’ here) for all further analyses. We analyzed the expression
pattern of the transgene in highly purified thymic stromal cell
populations by RT-PCR (Fig. 3). Expression of the HA-GFP cassette
faithfully reflected that of endogenous Aire, with substantial quantities
in mTECs and faint signals in DCs. Neither the transgene nor
endogenous Aire was expressed in cTECs (Fig. 3b). In subfractionated
MHC class II–high B7.1hi and MHC class II–low B7.1lo mTECs37,
transgene expression again closely mimicked that of endogenous Aire,
with substantially more in MHC class II–high B7.1hi mTECs (Fig. 3c).
Attempts to directly exploit GFP fluorescence for analyses of expres-
sion by histology or flow cytometry were hampered by insufficient
expression of the transgene (data not shown).
To visualize the fate of hemagglutinin-specific CD4+ T cells devel-
oping in AIRE-HA thymi, we crossed AIRE-HA mice with ‘TCR-HA’
mice expressing a transgenic TCR that recognizes a peptide of amino
acids 107–119 of influenza hemagglutinin (HA(107–119)) in the
context of I-Ed (ref. 38). The thymic cellularity of AIRE-HA 
TCR-HA mice was not significantly different from that of mice
expressing only the TCR-HA transgene (74.6  106 ± 25  106
(n ¼ 11) versus 84  106 ± 19  106 (n ¼ 8); P ¼ 0.58), and the
frequency of CD4+ SP cells was essentially identical (Fig. 4a). In the
CD4+ SP population, the frequency of cells expressing the TCR-HA
clonotype was lower in AIRE-HA  TCR-HA mice than in TCR-HA
control mice (13.4  106 ± 7.8  106 versus 33.4  106 ± 8.5  106).
About half of those CD4+ SP TCR-HA+ cells expressed CD25,
suggesting efficient differentiation into the Treg cell lineage (Fig. 4b).
In accordance with that observation, 23.9% ± 6.8% (3.5 105 ± 0.5
105) of CD4+TCR-HA+ cells in AIRE-HA  TCR-HA mice expressed
Foxp3, whereas the frequency of CD4+TCR-HA+Foxp3+ cells in TCR-
HA mice was negligible (corresponding to 7  102 ± 5  102 cells;
Fig. 4c). In vitro suppression assays showed that sorted CD4+ SP TCR-
HA+CD25+ thymocytes from AIRE-HA  TCR-HA mice efficiently
inhibited the proliferation of naive CD4+ TCR-HA+ T cells obtained
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Figure 3 Medulla-specific expression of HA-GFP with bacterial artificial
chromosome transgenesis. (a) Sorting gates (outlined ovals) used for the
isolation of cTECs (CD45–EpCAM+Ly51+) and mTECs (CD45–EpCAM+Ly51–;
left) as well as MHC class II–high B7.1hi and MHC class II–low B7.1lo
mTECs (right). (b,c) RT-PCR analysis of the expression of transgenic HA-
GFP and endogenous Aire in thymic stromal cell subsets (above lanes).
Serial fivefold dilutions (wedges) of cDNA prepared from sorted cells were
normalized to Actb transcripts (encoding b-actin) before PCR amplification
of HA-GFP and Aire transcripts. Mf, macrophage. Data are representative of
at least two experiments.
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from TCR-HA mice deficient in recombination-activating gene 2
(Fig. 4d). The peripheral phenotype of AIRE-HA  TCR-HA mice
reflected the situation in the thymus; a distinct TCR-HA+CD25+ subset
was present among CD4+ T cells (Supplementary Fig. 2 online).
To formally demonstrate that mTEC-derived antigen was causing
Treg cell differentiation in this mouse model system, we grafted
deoxyguanosine-treated thymi from E14 AIRE-HA fetuses into
TCR-HA mice. This experiment faithfully recapitulated the phenotype
of AIRE-HA  TCR-HA mice (Fig. 5a). In contrast, TCR-HA+ CD4+
SP cells in AIRE-HA  TCR-HA-WT bone marrow chimeras had a
phenotype identical to that of control TCR-HA-WT chimeras,
indicating that Aire locus–driven expression of HA in hematopoietic
cells, if existent, was too low to measurably affect T cell development
(Fig. 5b).
The TCR-HA system has been used in many settings to study Treg
cell development11,12,14,15. Therefore, we addressed whether Treg cell
differentiation after intrathymic antigen encounter might possibly
reflect an inherent predisposition of TCR-HA+ thymocytes. Targeting
of HA to DCs with a transgenic construct driven by the promoter
of the gene encoding CD11c39 resulted in complete deletion of TCR-
HA+ thymocytes, indicating that TCR-HA+
thymocytes can be deleted in the thymus
when appropriate conditions are met (Sup-
plementary Fig. 3 online).
We next addressed whether our findings in
the AIRE-HA  TCR-HA model could be
reproduced with a second model antigen and
another TCR transgene. We used a fusion
protein of HA and ovalbumin (OVA) con-
taining the OVA epitope (amino acids 323–
339) recognized by the DO11.10 TCR and
targeted the fusion protein to mTECs under
control of the Aire locus with a bacterial
artificial chromosome transgenic approach
similar to that described above. The T cell
phenotype of the resultant AIRE-OVA 
DO11.10 mice strongly resembled that of
AIRE-HA  TCR-HA mice; we detected
Foxp3+CD25+ Treg cells expressing the
DO11.10 TCR in the thymus and periphery
(Supplementary Fig. 4 online). These data
collectively indicated that self antigen expressed in mTECs can
efficiently induce the differentiation of Foxp3+CD25+ Treg cells.
DCs and mTECs present mTEC-derived antigen
Our experiments so far had established that expression of HA
exclusively in mTECs was sufficient for the differentiation of TCR-
HA+ thymocytes into Treg cells. The issue remained open, however, of
whether this confined expression pattern coincided with a similarly
restricted pattern of HA(107–119) presentation exclusively by mTECs
or whether mTEC-derived HA was eventually taken up, processed and
presented by thymic DCs. To directly measure presentation of
HA(107–119) by various thymic stromal cell populations from
AIRE-HA mice, we used the A5 T cell hybridoma, which expresses
the clonotypic TCR-HA and carries a GFP reporter transgene driven
by elements controlling the gene encoding interleukin 2 (ref. 40).
Titration of HA(107–119) into cocultures of A5 cells and wild-type
thymic DCs showed a dynamic range of GFP expression crossing three
orders of magnitude and starting from a detection limit of approxi-
mately 10 ng/ml (Fig. 6a). The dose-response curve obtained with
wild-type mTECs as APCs was essentially superimposable (Fig. 6a).
Antigen presentation assays with cTECs, mTECs and DCs isolated
ex vivo from AIRE-HA mice showed strong stimulation of A5 cells by
mTECs and weak yet significant stimulation by DCs, but no signifi-
cant stimulation by cTECs (Fig. 6b). To confirm that presentation of
HA(107–119) by DCs was indeed due to capture of mTEC-derived
antigen rather than to processing of endogenously expressed antigen,
we generated a series of bone marrow chimeras. Indeed, thymic DCs
isolated from WT-AIRE-HA chimeras stimulated A5 cells as effi-
ciently as did those from control AIRE-HA-AIRE-HA chimeras; in
contrast, DCs obtained from AIRE-HA-WT chimeras did not
stimulate A5 cells (Supplementary Fig. 5 online).
Presentation of HA(107–119) by MHC class II–high B7.1hi and
MHC class II–low B7.1lo mTECs isolated from AIRE-HA mice
reflected in a more pronounced way the difference between these
‘mature’ and ‘immature’ mTECs in terms of mRNA quantities
(Fig. 3c). Although MHC class II–high B7.1hi mTECs strongly
stimulated A5 cells, presentation by MHC class II–low B7.1lo mTEC
was barely measurable (Fig. 6c). These results collectively indicated
that antigen exclusively expressed by mTECs can be presented con-
comitantly by mTECs themselves as well as by DCs.
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Figure 5 Expression of HA in AIRE-HA thymic epithelium but not expression
in hematopoietic cells recapitulates the phenotype of AIRE-HA  TCR-HA
mice. (a) Phenotype of CD4+ SP thymocytes in wild-type or AIRE-HA thymi
grafted under the kidney capsules of TCR-HA recipients, analyzed 8–12
weeks after transplantation of deoxyguanosine-treated E14 thymi.
(b) Phenotype of CD4+ SP thymocytes in BALB/c wild-type recipients of
TCR-HA or AIRE-HA TCR-HA bone marrow. Numbers in quadrants indicate
percent TCR-HA+CD25+ cells (top right) or TCR-HA+CD25– cells (bottom
right) among CD4+ SP cells. Data are representative of two independent
experiments with at least seven grafts each (a) or ten chimeras each in two
independent experiments (b).
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Figure 6 Display of HA(107–119) by isolated mTECs and DCs but not by cTECs from AIRE-HA thymi.
(a) Dose-response curve of activity of the GFP reporter construct in A5 T hybridoma cells stimulated
by wild-type mTECs or DCs (key) plus HA(107–119) (concentration, horizontal axis). The frequency of
GFP+ cells after 17 h of coculture was determined by flow cytometry. Data are representative of two
experiments. (b) Stimulation of A5 cells after 17 h of culture together with cTECs, mTECs or DCs from
AIRE-HA thymi (dark gray) or wild-type thymi (light gray). NS, not significant. Data are representative
of more than five independent experiments. Stimulation of A5 cells after 17 h of culture together with
MHC class II-high B7.1hi and MHC class II–low B7.1lo mTECs from AIRE-HA thymi (dark gray) or wild-
type thymi (light gray). Data are representative of two independent experiments.
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Treg cell selection independent of hematopoietic cells
The detection of mTEC-derived antigen presented on thymic DCs
raised the issue of whether the generation of Treg cells in AIRE-HA 
TCR-HA mice was orchestrated autonomously by mTECs or by DCs
that captured and presented mTEC-derived antigen. If the latter were
true, experimental interference with the capacity of DCs to present
antigen would abolish Treg cell differentiation. The fact that mice with
targeted mutation of the gene encoding I-Ed, to which the TCR-HA is
restricted, have not been generated rendered a straightforward
approach with I-Ed-deficient bone marrow impossible. Therefore, as
an alternative strategy, we made use of the fact that TCR-HA+ T cells
neither ‘alloreact’ to C57BL/6 (H-2b) APCs nor recognize cognate HA
peptide in the context of I-Ab (data not shown).
We generated bone marrow chimeras with athymic mice by
reconstituting irradiated C57BL/6 nude mice (H-2b) with H-2b
TCR-HA bone marrow (called ‘H-2b(nude-TCR-HA)’ here) or
BALB/c nude mice (H-2d) with H-2d TCR-HA bone marrow (called
‘H-2d(nude-TCR-HA)’ here). Subsequently, we engrafted those
chimeras with deoxyguanosine-treated AIRE-HA thymi (AIRE-
HA-H-2b(nude-TCR-HA) and AIRE-HA-H-2d(nude-TCR-
HA)) or wild-type thymi (WT-H-2b(nude-TCR-HA) and WT-
H-2d(nude-TCR-HA)) obtained from BALB/c (H-2d) E14 donors.
Positive selection of CD4+ TCR-HA+ cells would in all situations be
mediated by H-2d thymic epithelium. The fate of TCR-HA+ cells in
AIRE-HA-H-2d(nude-TCR-HA) grafts was expected to emulate that
of AIRE-HA  TCR-HA mice. In AIRE-HA-H-2b(nude-TCR-HA)
grafts, however, Treg cell development, depending on its requirement for
the presentation of mTEC-derived antigen by hematopoietic APCs,
would or would not occur.
We analyzed grafts 6–8 weeks after transplantation. The size of the
CD4+ SP compartment was not very different among the experimental
groups (Fig. 7a). Somewhat unexpectedly, we consistently detected
fewer TCR-HA+ cells among CD4+ SP cells for WT-H-2b(nude-
TCR-HA) thymi than for WT-H-2d(nude-TCR-HA) thymi (in the
absence of cognate antigen; Fig. 7b). We deem it likely that this was a
passive, indirect effect due to less-stringent DC-imposed ‘censorship’
of thymocytes expressing endogenously rearranged TCRs (such as
TCR-HA– CD4+ SP cells) in thymi with a MHC-mismatched (H-2b)
hematopoietic compartment. Given that, the phenotypes of AIRE-
HA-H-2d(nude-TCR-HA) thymi and AIRE-HA-H-2b(nude-
TCR-HA) thymi were very similar. The frequency of TCR-HA+ cells
among CD4+ SP cells was in both cases lower than that in control
thymi (Fig. 7b). TCR-HA+ CD4+ SP populations in both experimental
groups that received AIRE-HA thymi contained similarly high fre-
quencies of Foxp3+CD25+ cells, whereas only minute populations of
cells with that phenotype were detectable in the absence of cognate
antigen (Fig. 7a,b).
To verify expression of the expected MHC haplotypes by hemato-
poietic APCs, we digested one third of each graft with collagenase
and analyzed the resulting cell suspensions by flow cytometry.
Most DCs from H-2b(nude-TCR-HA) recipients expressed I-Ab,
whereas cells expressing I-Ad were essentially undetectable (Fig. 7c).
These data confirmed efficient seeding of thymic grafts with host-
derived hematopoietic APCs. In summary, our findings indicate
that Treg differentiation of TCR-HA
+ thymocytes resulting from
expression of HA exclusively in mTECs did not require cross-
presentation of HA by thymic DCs but instead was autonomously
mediated by mTECs.
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Figure 7 Efficient generation of Foxp3+CD25+ Treg cells independently of cross-presentation by hematopoietic cells. (a) Cellular composition of
deoxyguanosine-treated AIRE-HA or wild-type thymi (H-2d) at 6–10 weeks after being grafted into H-2d(nude-TCR-HA) or H-2b(nude-TCR-HA) recipients.
Numbers above outlined areas or in top right quadrants indicate the frequency (± s.d.) of CD4+ SP cells (top row), of TCR-HA+CD25+ cells in the CD4+ SP
population (middle row) or of Foxp3+CD25+ cells among gated CD4+ SP TCR-HA+ cells (bottom row). All plots show data after gating on CD45.1+ cells to
identify TCR-HA thymocytes (nude mice and thymus grafts were CD45.2+). Data were calculated from three independent experiments (WT-H-2d(nude-
TCR-HA), n ¼ 8 chimeras; AIRE-HA-H-2d(nude-TCR-HA), n ¼ 8 chimeras; WT-H-2b(nude-TCR-HA), n ¼ 7 chimeras; AIRE-HA-H-2b(nude-TCR-
HA), n ¼ 19 chimeras). The cellularity of grafts varied considerably within experimental groups, but was not substantially different between groups (data
not shown). (b) Summary of the data in a. Left, percent TCR-HA+ cells among CD4+ SP cells; right, percent Foxp3+CD25+ cells among gated CD4+ SP
TCR-HA+ cells. TG, AIRE-HA transgenic. (c) Carryover of donor-derived CD11c+ DCs in deoxyguanosine-treated grafts. Expression of I-Ad and I-Ab on gated
CD45+CD11c+ cells in H-2d(nude-TCR-HA) or H-2b(nude-TCR-HA) recipients was analyzed in thymic cell suspensions prepared by enzymatic digestion.
Numbers in quadrants indicate percent cells (± s.d.) in each. Data are representative of at least four grafts each.
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DISCUSSION
Using two complementary approaches, we have provided evidence
here for an autonomous function of mTECs, which act concomitantly
as antigen-expressing and antigen-presenting cells in Treg cell genera-
tion. Our initial experiments with RTOCs from material rigorously
purged of hematopoietic cells provided unambiguous evidence in
favor of the idea that TECs are sufficient to support polyclonal Treg cell
development. Our observations support a model whereby TEC-
thymocyte interactions shape the Treg cell compartment and dominant
tolerance, whereas hematopoietic APCs (mainly thymic DCs) mediate
deletional tolerance.
A study of the selection of ‘superantigen-reactive’ Treg cells in the
absence or presence of MHC class II on hematopoietic cells reached
similar conclusions in terms of the general function of the thymic
epithelium during Treg cell development
41. However, delineation of the
respective contribution of medullary versus cortical TECs remained
experimentally challenging. When MHC class II expression is restored
in MHC class II–deficient mice with a purportedly cTEC-specific
transgene, a functional CD25+CD4+ T cell pool of ‘normal’ size is
selected17. Those results suggest that interactions of developing
thymocytes with MHC class II on cTECs are sufficient to support
Treg cell differentiation. However, in that system it remains unclear
whether mTECs truly lack MHC class II; this caveat and concern is
particularly valid, given the notorious propensity of mTECs to
‘ectopically’ express transgenes26.
Taking advantage of the clonal origin of medullary ‘islands’, we
generated chimeric RTOCs in which individual medullae either
expressed or lacked MHC class II (ref. 35). The significantly fewer
Foxp3+ Treg cells in medullae lacking MHC class II supported the idea
of involvement of mTEC-thymocyte interactions in generating the
polyclonal Treg cell pool. Several scenarios might account for the
residual Foxp3+ cells in MHC class II–deficient medullae. First, small
clones of MHC class II–positive mTEC positioned adjacent to MHC
class II-negative regions may have disappeared eventually, whereas
their ‘footprint’ in the local Treg cell compartment may have persisted
for some time. This dynamic nature of medulla morphology over time
has been reported before42,43. Second, the possibility of lateral move-
ment of Foxp3+ cells generated in more distant MHC class II–positive
medullae cannot be formally excluded. Finally, initially stochastic
(antigen-independent) specification of Treg cell fate may initially
occur in the cortex. After migration of thymocytes from the cortex
to the medulla, interactions with cognate antigen on mTECs may then
serve to selectively induce the survival and/or population expansion of
otherwise short-lived precursors.
The phenotype of mice deficient in tumor necrosis factor receptor–
associated factor 6 (TRAF6) supports the idea that mTEC-thymocyte
interactions are critical for Treg cell generation
44. Absence of TRAF6
from the thymic epithelium is associated with general autoimmunity,
most likely as a result of a disorganized medullary compartment
lacking ‘mature’ AIRE+ mTECs, the exact cell type to which HA was
targeted in our model. The CD4+ SP compartment of TRAF6-
deficient mice was mostly devoid of CD25+ Treg cells. A complemen-
tary study of the involvement of TRAF6 in T cells has shown that this
lack of Treg cells is not due to a T cell–intrinsic requirement for
TRAF6, as functional Treg cells arise when TRAF6 is ablated specifically
and only in T cells45. Our findings may explain why the autoimmunity
caused by TRAF6 deficiency in thymic epithelium seems more severe
than that in AIRE-deficient mice20. AIRE deficiency leads to lower
expression of peripheral antigens in otherwise apparently normal
‘mature’ mTECs23. TRAF6 deficiency more profoundly results in a
complete absence of such cells and thus also affects any tolerogenic
function of mTECs beyond their function as a reservoir of tissue-
specific antigens.
A chief limitation inherent to analysis of the polyclonal Treg cell
repertoire is that the function of specific antigen during Treg cell
selection remains mostly obscure. Therefore, we complemented our
observations with studies in systems involving defined antigen speci-
ficity. Targeting of HA as well as OVA to mTECs efficiently directed
TCR-transgenic CD4+ T cells of the cognate TCR specificity into the
Treg cell lineage, whereas DC-specific expression of HA led to the
deletion of TCR-HA+ thymocytes.
Those data suggested that the APC type specifies the outcome of
the recognition of self antigen, with the caveat that expression of
self antigen in mTECs cannot necessarily be interpreted to mean
that the ensuing mode of tolerance is in fact a result of antigen
presentation by mTECs29. Indeed, direct assessment of antigen
presentation in the AIRE-HA model demonstrated several salient
features of antigen routing in this system. First, both mTECs and
DCs, but not cTECs, presented substantial amounts of HA(107–119).
Second, presentation of HA(107–119) by DCs was the result of
acquisition and processing of mTEC-derived antigen. Third,
presentation by mTECs was most likely due to endogenous
MHC class II loading rather than antigen transfer in the mTEC
compartment. Regardless of their limited ability to process exo-
genous antigens, mTECs presented HA(107–119) far more efficiently
than did DCs, which are arguably better indicators of freely
available antigen46.
Using chimeras with MHC-mismatched thymi and bone marrow,
we ruled out the possibility that transfer of mTEC-derived antigen to
DCs was essential for the generation of TCR-HA+ Treg cells. This
finding contrasts with the strict requirement for transfer of mTEC-
derived antigen to hematopoietic cells during deletion of OT-II CD4+
thymocyes in the ‘RIP-mOVA’ model29. These findings collectively
support the idea that the modalities of routing of mTEC-derived self
antigens are indeed a critical parameter in specifying recessive or
dominant mechanisms of tolerance. We deem it likely that such
considerations might likewise apply to different epitopes derived
from a given self antigen.
How likely is it that the nature of the stromal cell presenting mTEC-
derived antigen (mTECs themselves versus ‘cross-presenting’ DCs) is
the sole determinant of whether recessive or dominant tolerance is
induced? Differentiation of TCR-HA+ cells into the Treg cell lineage in
AIRE-HA  TCR-HA mice coincided with much lower absolute
numbers of these cells than in TCR-HA control mice. According to
a strictly qualitative model, this may have occurred through deletion
of a certain fraction of TCR-HA+ cells after antigen recognition on
DCs concomitant with Treg cell selection by mTECs. However,
elimination of the capacity of DCs to present mTEC-derived antigen
did not restore the frequency of TCR-HA+ cells. Thus, it seems that
even in conditions in which HA is presented exclusively by mTECs,
deletion and Treg cell selection occur ‘side by side’. Several mutually
nonexclusive explanations exist. First, it is possible that the strength of
agonistic signals delivered by mTECs in our model is close to a
threshold that may distinguish deletion from Treg cell selection; hence,
small fluctuations in antigen expression in mTECs may ‘tip the
balance’ in favor of one or the other mode of tolerance. Second,
functional heterogeneity in the mTEC compartment (for example,
varying amounts of costimulatory molecules) may influence the
outcome of deletion versus Treg cell fate specification. Evidence
suggests that CD28-B7 interactions may be involved47–50. Finally,
the possibility of stochastic heterogeneity among thymocytes, even
those expressing an identical TCR, regarding the predisposition to
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differentially respond to antigenic stimuli delivered by mTECs cannot
be ruled out.
Our conclusion that interactions with AIRE+ mTECs shape the Treg
cell repertoire is not incompatible with the fact that the autoimmunity
in AIRE-deficient mice has been ascribed mainly to a defect in
deletional rather than dominant tolerance23. Mutations in Aire may
change the profile of peptide–MHC class II complexes displayed on
mTECs in a very subtle way. At the same time, Aire-deficient mTECs
can still be expected to present a plethora of self antigens and thus may
contribute to the generation of a sufficiently diverse Treg cell repertoire.
Consistent with that idea, even mice expressing a single MHC class II–
bound peptide have a Treg cell repertoire of considerable diversity
9. It
remains unclear in how far antigen-specific ‘holes’ in the Treg cell
repertoire may eventually predispose to autoimmunity.
We propose that mTECs provide a critical niche that fosters Treg cell
development. Based on considerations pertaining to Treg cell ontogeny
and positioning in the thymic microenvironment, the existence of
such a niche has been postulated before, although its exact nature
(hematopoietic or epithelial) has remained unclear18. What is the
function of this niche? At first, the enormous increase in the number
of antigen-specific Treg cells triggered by the presentation of endogen-
ously expressed antigen by mTECs may suggest de novo induction of a
Treg cell phenotype. However, our observations are also compatible
with a stochastic component of Treg cell development
51. Thus, selec-
tion and/or population expansion of stochastically ‘primed’ Treg cell
precursors may require, in addition to agonistic antigen, external cues
specifically provided by mTECs. Deciphering the molecular ‘signature’
of this mTEC niche in terms of critical surface molecules and/or
soluble factors should provide additional insights into Treg cell devel-
opment. Signaling via CD28 (ref. 49) as well as through the thymic
stromal lymphopoietin receptor52 has been shown to directly induce
Foxp3 expression in thymocytes in vitro. Consistent with our proposi-
tion, their ligands (B7 and thymic stromal lymphopoietin, respec-
tively) are abundantly provided by mTECs.
METHODS
Mice. Animals were bred in the animal facility of the Research Institute of
Molecular Pathology in individually ventilated cages. C57BL/6 nude and
BALB/c nude mice were from Taconic; other strains were from ‘in-house’
breeding colonies. All animal studies were approved by local authorities
(MA58) and were done according to Austrian regulations. The generation of
transgenic mice is described in the Supplementary Methods online.
Antigen presentation assay. Thymic stromal cells (2  104) from wild type or
AIRE-HA mice were cultured together with A5 T hybridoma cells (2  104) in
200 ml Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 1%
(vol/vol) FCS in 96-well round-bottomed plates. Then, 17 h later, stimulation
was measured by flow cytometry of GFP reporter expression on gated
TCR-HA+CD4+ cells. Equal input numbers of APCs (except in experiments
with B7.1hi and B7.1lo mTEC subsets) were ensured by verification that similar
stimulation was achieved with saturating amounts (10 mg/ml) of exogenous
HA(107–119).
Suppression assays. Sorted CD25+TCR-HA+ CD4+ SP T cells (2  104) from
AIRE-HA thymi and/or naive TCR-HA+ CD4+ T cells (2  104) enriched by
magnetic-activated cell sorting from spleen and lymph nodes of TCR-HA mice
deficient in recombination-activating gene were cultured together with irra-
diated (3,000 rads) BALB/c splenocytes (2 105) in the presence of 10 mg/ml of
HA(107–119). Proliferation was measured by scintillation counting after cells
were pulsed with 1 mCi [3H]thymidine per well for the last 20 h of a 96-hour
incubation period.
Preparation of thymic stroma. Thymi from 2-week-old mice were cut into
small pieces and were digested at 37 1C in IMDM containing 0.2 mg/ml of
collagenase (Roche), 0.2 mg/ml of dispase I (Roche), 2% (vol/vol) FCS, 25 mM
HEPES, pH 7.2, and 25 mg/ml of DNase I, followed by incubation for 5 min in
5 mM EDTA. Cells were washed and were resuspended in Percoll (r, 1.115; GE
Healthcare). A discontinuous gradient was then generated by the addition of a
layer of Percoll (r, 1.050) followed by a layer of PBS on top of this cell
suspension. Gradients were spun for 30 min at 1,350g at 4 1C, and low-density
cells were collected from the upper interface, washed and stained for sorting by
flow cytometry.
RTOC. Single-cell suspensions of E14 fetal lobes were prepared by enzymatic
digestion (described above). Samples were depleted of CD45+ cells with
biotinylated CD45-specific monoclonal antibody and streptavidin MACS beads
(Miltenyi Biotech) according to standard procedures. Cells were ‘spun down’
and were resuspended at a density of approximately 1  106 cells/ml. Drops of
0.2–0.4 ml were deposited onto 0.45-mm nylon membranes (Millipore) sup-
ported by Gelfoam sponges (Pharmacia & Upjohn) in six-well plates containing
3 ml IMDM and 10% (vol/vol) FCS. RTOCs were incubated for 48 h
before transplantation.
Deoxyguanosine treatment. E14 thymic lobes were placed on 0.45-mm
membrane filters (Millipore) supported by Gelfoam (Pharmacia&Upjohn)
and were incubated for 5 d with 10% (vol/vol) IMDM supplemented with
1.35 mM 2-deoxyguanosine before transplantation.
Immunofluorescence. Frozen sections 11 mm in thickness were fixed in cold
acetone, were washed and were blocked for 20 min with 10% (vol/vol) FCS in
PBS, followed by incubation overnight with the appropriate primary anti-
bodies: Foxp3-specific polyclonal rabbit serum, MTS10 supernatant (rat
immunoglobulin M) and/or biotinylated antibody to MHC class II (anti–
MHC class II; P7/7). Sections were incubated with secondary antibodies for 2 h
at 21 1C after being washed three times for 15 min each in 0.1% (vol/vol)
Tween 20 in PBS. Secondary reagents were Alexa Fluor 488–conjugated anti-rat
immunoblobulin M (Molecular Probes), indocarbocyanine-conjugated anti-
rabbit (Jackson ImunoLaboratories) and/or indocarbocyanine-conjugated
streptavidin (Jackson ImmunoLaboratories). MHC class II–positive or MHC
class II–negative medullae were identified in consecutive sections through
entire grafts for verification of the absence of MHC class II–positive cells in
three dimensions. The volume of the respective medullary segments was
determined as follows: area of the MTS10+ medullary region (in mm2) 
thickness of the section (in mm). The number of Foxp3+ cells per unit volume
in MHC class II–positive and MHC class II–negative medullary regions was
determined and the mean value was calculated.
Statistical analysis. Statistical significance was assessed by the two-tailed
Student’s t-test.
Note: Supplementary information is available on the Nature Immunology website.
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Supplementary Figure 1 Generation of mixed RTOC (outline of the experimental
procedure). Equal numbers of CD45-depleted fetal thymic stromal cells were combined
to generate mixed RTOCs. Six to eight weeks after grafting into MHC– recipients,
MHCII+ and MHCII– medullary “islands” of clonal origin are found.
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Supplementary Figure 2 A distinct population of TCR-HA+CD25+Foxp3+ cells among
peripheral CD4+ T cells in AIRE-HA • TCR-HA mice. (a) Lymph node cells of AIRE-HA •
TCR-HA mice and TCR-HA controls were stained with antibodies specific for CD4, CD8,
TCR-HA and CD25. Expression of TCR-HA versus CD25 is shown on gated CD4+ T cells.
Frequencies of cells representative of more than 9 mice analyzed from each group are
depicted in the respective quadrants. (b) Expression of Foxp3 mRNA in sorted TCR-HA+
CD4+ T cells from AIRE-HA • TCR-HA mice and TCR-HA controls was measured by RT-
PCR using serial dilutions (5-fold) of RNA. Data are representative of two independent
experiments.
Suppl. Fig. 2
0.6
Foxp3
Actb
63
TCR-HA AIRE-HA ×TCR-HA
TCR-HA
C
D
25
33.8
0.4
4.2
5.9
0.3
0.1
CD11c-HA ×TCR-HA
Suppl. Fig. 3
Supplementary Figure 3 Targeting of HA to DCs in CD11c-HA × TCR-HA 
mice results in efficient intra-thymic deletion of TCR-HA+ cells. To test 
whether TCR-HA cells are deleted when HA is abundantly expressed by 
thymic DCs, we targeted HA expression to DCs under control of the promoter 
driving expression of the gene encoding CD11c. Thymocytes from CD11c-HA 
× TCR-HA mice and TCR-HA controls were stained with the indicated 
antibodies. Expression of TCR-HA versus CD25 is shown on gated CD4+ SP 
thymocytes. The phenotype of AIRE-HA × TCR-HA mice is shown on the right 
for comparison.
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Supplementary Figure 4 Targeting of OVA to mTECs leads to generation of OVA-
specific CD25+Foxp3+ Treg cells. A fusion protein of HA and OVA containing the 
OVA323-339 epitope recognized by the DO11.10 TCR was targeted to mTECs using a 
BAC transgenic approach. (a) Thymocytes of AIRE-OVA × DO11.10 or DO11.10 control 
mice were stained with the indicated antibodies and analyzed by flow cytometry. Numbers 
in quadrants indicate the percentage of cells of the respective phenotype.  (b) Thymic
selection of KJ1-26+ Treg cells in the periphery of AIRE-OVA × DO11.10 mice. Plots 
depict CD4+ lymph node T cells from indicated mice. Data in (a) and (b) are 
representative of at least 5 animals of the respective genotype.
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Suppl. Fig. 5
Supplementary Figure 5 Presentation of HA107-119 by 
DCs resulting from capture of mTEC-derived antigen.
Thymic DCs were isolated from the indicated groups of 
bone marrow chimeras and their ability to stimulate Il2
GFP-reporter expression in A5 T hybridoma cells was 
assessed. Data are representative of two independent 
experiments.
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Supplementary Methods 
Transgenic mice 
To generate AIRE-HA mice, a cDNA encoding a fusion protein of HA and GFP followed 
by a poly-A signal was inserted by homologous recombination in bacteria1 into the 
mouse BAC RP23-1146F6 (BACPAC). In brief, the BAC was modified using a targeting 
vector containing homology boxes spanning nucleotides -379 to -2 (5’) and 17 to 399 (3’) 
surrounding the HA-GFP cDNA and a poly-A signal followed by a neomycin resistance 
(neor) gene flanked by FRT-sites. After selection of successfully recombined clones, the 
neor cassette was removed. Transgenic mice were generated by injection of 
supercoiled BAC DNA into pronuclei of C57BL/6 × CBA F1 zygotes. Mice were 
backcrossed to the BALB/c background for at least three generations before analysis. 
For the generation of AIRE-OVA mice, a cDNA encoding a fusion protein of HA and 
OVA was inserted into BAC RP23-77O11 (BACPAC) replacing the start codon of the 
Aire gene using the strategy depicted above. Briefly, a portion of cDNA encoding the 71 
C-terminal amino acids (314-385) of OVA was cloned 3′ of the HA cDNA. The resulting 
membrane-bound fusion protein carries the OVA323-339 epitope in its cytoplasmic tail. 
Transgenic mice were generated by injection of supercoiled BAC DNA into pronuclei of 
C57BL/6 × CBA F1 zygotes. Mice were backcrossed to the BALB/c background for at 
least three generations before analysis. For the generation of CD11c-HA mice, the HA 
cDNA was inserted into the EcoRI site of a vector containing the promoter of the gene 
encoding CD11c (kindly provided by T. Brocker, Munich, Germany) as previously 
described2. The resulting plasmid DNA was linearized by XhoI and NotI digestion and 
was injected into fertilized BALB/c oocytes. 
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Antibodies and flow cytometry 
Biotin-conjugated monoclonal antibodies (mAbs) specific for CD4 (GK 1.5), CD8 (53-
6.7), I-Ad, CD80 (B7.1, 16-10A1), phycoerythrin-conjugated mAbs specific for CD25 
(PC61), CD45.1 (A20), Ly51 (6C3), the DO11.10 TCR (KJ1-26), mAbs specific for CD8 
(53-6.7), CD45 (Ly-5), CD4 (GK1.5), phycoerythrin-Cy7-conjugated mAb specific for 
CD25 (PC61), allophycocyanin-Cy7-conjugated mAb specific for CD4 (GK1.5), 
allophycocyanin-conjugated streptavidin and cychrome-conjugated streptavidin were 
purchased from Becton Dickinson. mAbs specific for TCR-HA (6.5), EpCAM (G8.8), I-Ab 
(Y3P) and pan-MHC class II (P7.7) were purified from hybridoma supernatants and 
conjugated to FITC or Alexa 647 in our lab. Foxp3 intracellular staining was performed 
according to the manufacturer’s recommendations using PE- or APC-conjugated anti-
mouse Foxp3 (eBiosciences). Flow cytometric analysis was performed on a 
FACSCanto flow cytometer (Becton Dickinson) using FACS DIVA software (Becton 
Dickinson). 
Semi quantitative RT-PCR 
mRNA was extracted using the High Pure RNA Isolation Kit (Roche). RNA was 
subjected to oligo(dT)-primed reverse transcription with a cDNA synthesis kit 
(Invitrogen). The PCR primers were: Aire, 5′-ACCATGGCAGCTTCTGTCCAG-3′ and 5′-
GCAGCAGGAGCATCTGCAGAG-3′; HA-GFP, 5′-CTAATGGATCTTTGCAGTGC-3′ 
and 5′-GGCTGTTGTAGTTGTACTCC-3′; Actb, 5′-
TGGAATCCTGTGGCATCCATGAAAC-3′ and 5′-
TAAAACGCAGCTCAGTAACAGTCCG-3′; Foxp3: 5′-CAG CTG CCT ACA GTG CCC 
CTA G-3′ and 5′-CAT TTG CCA GCA GTG GGT AG-3′. PCR conditions for Aire were 
68
94°C for 3 min., 30 cycles of 94°C for 45 s, 61°C for 45 s, 72°C for 1.5 min. PCR 
conditions for GFP were 94°C for 3 min, 37 cycles of 94°C for 45 s, 60°C for 45 s, 72°C 
for 1.5 min. PCR conditions for Actb were 94°C for 3 min., 29 cycles of 94°C for 45 s, 
58°C for 45 s, 72°C for 1 min. PCR conditions for Foxp3 were 94°C for 3 min, 36 cycles 
of 94°C for 30 s, 61.8°C for 30 s, 72°C for 30 s. 
Bone marrow chimeras 
Mice were lethally irradiated (2 x 450 Rad for BALB/c and 2 x 550 Rad for C57BL/6) and 
received a total of 8 x 106 T cell-depleted bone marrow cells. Chimeras were analyzed 
6-8 weeks after reconstitution. For combined bone marrow and thymus chimeras, 
BALB/c nude (CD45.2+) or C57BL/6 nude (CD45.2+) mice were lethally irradiated as 
above and reconstituted with TCR-HA+CD45.1+H-2d or TCR-HA+CD45.1+H-2b bone 
marrow. 3-4 weeks after bone marrow transfer mice received grafts of dGUO-treated 
WT or AIRE-HA H-2d CD45.2+ E14 thymi under the kidney capsule. Grafts were 
analyzed 6-8 weeks after transplantation. Some grafts in C57BL/6 nude recipients were 
left in place for up to 4 months without evidence for tissue-rejection. 
 
1. Yang, X.W., Model, P. & Heintz, N. Homologous recombination based 
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2. Brocker, T., Riedinger, M. & Karjalainen, K. Targeted expression of major 
histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells 
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Abstract 
 
Fms-like tyrosine kinase 3 ligand (FLT3L) plays a major role in dendritic cell 
(DC) biology. Deficiency of FLT3L causes a dramatic decrease in DC 
numbers whereas increasing its availability (by repetitive injections for 7-10 
days) leads to a 10-fold increase in DC numbers. Here, we show that FLT3L 
treatment indirectly leads to an expansion of peripheral naturally occurring T 
regulatory (NTreg) cells. The FLT3L-induced increase in NTreg was still 
observed in thymectomized mice, ruling out the role of the thymus in this 
mechanism. Instead, the increased number of NTreg was due to proliferation 
of pre-existing NTreg, likely due to favoured interactions with increased 
number of DC. In vitro, we show that DC induce Treg proliferation by direct 
cell contact and in an IL-2 dependent, TCR independent manner. FLT3L 
treatment had no effect on normal immune response but could prevent death 
induced by acute Graft vs Host Disease (GvHD). This study demonstrates 
unique aspects in the regulation of Treg homeostasis by DC, which were 
unappreciated until now. It also re-enforces the relevancy of FLT3L treatment 
in transplantation or autoimmune settings by its ability to increase both the 
number of immature tolerizing DC and NTreg. 
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Introduction 
Fetal-liver kinase 2/FMS-like tyrosine kinase 3 (FLK2/FLT3) is a receptor 
tyrosine kinase, which was initially cloned from fetal liver population enriched 
with hematopoietic stem cell activity 1. FLT3 has sequence and structural 
homology with c-kit and is expressed mostly by hematopoietic cell progenitors 
and dendritic cells (DC) 2-4. FLT3L is the only known ligand for FLT3. 
Both FLT3 and FLT3L-deficient mice are viable, fertile and hematopoiesis is 
maintained in the absence of FLT3 signalling 5,6. The most striking 
phenotypes of these mice are the decrease in lymphoid and myeloid bone 
marrow progenitors as well as a decrease in DC and NK cell numbers. As 
expected from data obtained in FLT3L-deficient mice, administration of FLT3L 
by repetitive injections leads to an increase in the number of bone marrow 
progenitors as well as DC and NK cells 7-10. Moreover, our previous work 
showed that increased FLT3L availability had an inhibitory effect on B cell 
lymphopoiesis suggesting that, when present in supra-physiological levels, 
FLT3L could enhance myeloid over lymphoid differentiation 10. 
DCs play a dual role in the immune system. They are responsible for inducing 
an immune response or tolerance to self or non-innocuous antigens 
depending on their maturation/activation state 11,12. In an immature state, DC 
express low levels of MHC class II antigens and costimulatory molecules and 
are thought to induce T cell tolerance by several distinct mechanisms12. 
Maturation of DC is induced by pathogens or endogenous “danger signals” 
sensed through a variety of receptors, which upon ligand binding induce MHC 
class II and costimulatory molecule up-regulation as well as inflammatory 
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cytokines secretion. Once in a mature state, DC prime T cells and induce 
immune response13.  
There is a considerable literature suggesting that DC influence regulatory T 
cell biology. Regulatory T cells (Treg) encompass T cell population, which 
prevent harmful immune responses against self 14,15. Among Treg cells, the 
so-called naturally occurring CD4 regulatory T cells (NTreg) are the best 
characterized. This lineage is defined by the expression of the transcription 
factor Foxp3 16-18, a natural mutation or conditional deletion of Foxp3 leads to 
lethal autoimmune disease, due to absence of functional NTreg 19-22. NTreg 
develop in the thymus 15 but conversion from effector to regulatory cells can 
take place in the periphery and in some experimental settings, DC were 
demonstrated to be instrumental in this process 23-26.   
Little is known about the rules governing NTreg homeostasis in the periphery 
in normal conditions but it is clear that IL-2 is indispensable for NTreg survival 
whereas it is dispensable for their development in the thymus 27,28. In IL-2 
deficient mice, NTreg development still takes place in the thymus but cells die 
rapidly after thymic egress because of lack of IL-2-mediated survival signals. 
Consequently, IL-2 deficient mice suffer from autoimmune disease because of 
the lack of peripheral NTreg 29,30. In addition, CD28 signalling has been shown 
to be implicated in thymic NTreg development as well as peripheral survival 
31,32. In a diabetes model, CD28 blockade or deficiency exacerbates 
autoimmune symptoms 32. Finally, NTreg are known to proliferate upon 
antigen encounter in vivo 33-36.  
In the present study, we investigated the influence of FLT3L-mediated 
increase of DC numbers on regulatory T cell homeostasis. We demonstrate 
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that repetitive injections of FLT3L lead to expansion of NTreg cells in the 
periphery. NTreg increase was due to proliferation of pre-existing Treg, likely 
due to favoured interactions with DC. Experiments conducted in vitro showed 
that DC-induced Treg proliferation was IL-2 dependant, TCR independent and 
required an additional contact-dependent DC-mediated signal whose nature 
currently remains unknown.  
FLT3L treatment prevented death induced by acute GvHD but did not impair 
normal immune response. This represents a new aspect of Treg homeostasis 
and might provide alternative ways of controlling Treg biology in vivo. 
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Materials and methods 
 
Mice 
C57Bl/6, C57Bl/6.Ly5.1, DBA/2 and (C57Bl/6 x DBA/2)F1 FLK3L k.o.6 mice 
were bred in our animal facility. MHC class II deficient mice 37 were obtained 
from Taconic farms and C57Bl/6 Foxp3EGFP reporter mice 38 were a kind gift 
from Prof. Malissen. All mice were used between 7 to 16 weeks of age and 
were maintained in specific pathogen–free conditions. All animal experiments 
were carried out within institutional guidelines. Mice were humanely killed by 
CO2 inhalation and organs removed by standard procedures.  
 
Thymectomies 
At 4 to 6 weeks of age, mice were anesthetized and thymus was removed by 
suction through a small upper sternal incision. That thymectomy had been 
complete was verified in each animal by anatomical inspection at the time of 
sacrifice. 
 
FLT3L treatment 
Recombinant human FLT3L (rFLT3L) was a kind gift of Amgen (Thousand 
Oaks, CA). A stock solution containing 1mg rFLT3L/mL was prepared in PBS 
and aliquots stored at –20°C until use. For FLT3L treatment, mice generally 
received 10-20 µg rFLT3L (0.2 mL) by intraperitoneal injection daily or every 
second day for 10 days, a treatment schedule previously used to increase DC 
number. In titration experiments ("Results"), mice were treated with graded 
doses of 2 or 10 µg/0.2-mL injections.  
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Bone marrow chimeras 
Bone marrow cell suspensions from donor mice were prepared by flushing 
femurs and tibias with PBS using a 23-g needle. After red blood cell lysis, T 
cells were depleted by re-suspending cells in a mixture of rat IgM anti-CD90 
(AT83) anti-CD4 (RL172) and anti-CD8 (31 M) mAb hybridoma supernatants 
and incubated for 20 min at 4°C. Following a washing step, antibody-coated 
cells were lysed by adding rabbit complement dissolved in serum-free 
Dulbecco's modified Eagle's medium (DMEM). After incubation for 45 min at 
37°C, cells were washed and resuspended in DMEM prior to injection. Hosts 
were lethally γ-irradiated with a single dose of 950 cGy using a Cobalt source 
(Gammacell 40, Atomic energy of Canada, Ltd) prior to receiving 5x106 cell 
intravenously. 
 
Cell preparation 
Single-cell suspensions from thymus or spleen were prepared by pressing 
through a 100-µm nylon mesh into 2% FCS IMDM. For flow cytometry, cells 
were washed and resuspended in PBS containing 2% FCS and 0.1% sodium 
azide (FACSwash). Viable cells were stained with trypan blue and counted in 
a hemocytometer. The total number various lymphocytes subpopulations 
were calculated from the frequency estimated by FACS analysis and the total 
number of living cells recovered per organ.  
 
Flow cytometry 
The following mAbs were used: anti-B220 (RA3-6B2), anti-CD3 (145.2c11), 
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anti-CD4 (RM4-5), anti-CD11c (HL3), anti-DX5 (DX5) and anti-Ki67 (B56) 
were purchased from BDbioscience; anti-NK1.1 (PK136) and anti-FoxP3 
(mAb FJK-16S) were purchased from eBioscience; anti-CD4 (GK1.5), anti-
CD8α (53-6-72) anti-CD19 (1D3), anti-CD45.2 (1D4-2.1) and anti-pan MHC 
class II (M5) antibodies were purified from the hybridoma supernatant and 
labeled by standard methods. Cell surface staining was performed as 
previously described, and analyses were performed on a FACSCalibur 
interfaced to a Macintosh computer with BD Biosciences/CellQuest or Flowjo 
software. Dead cells were excluded from analysis by a combination of light 
scatter and/or absence of propidium iodide (PI) staining. Intracellular staining 
for FoxP3 and Ki67 were performed according to the manufacturer’s 
instructions (eBioscience) and (BDbioscience). Cell sorting was performed on 
a FACSAria (BD Biosciences). 
 
In vitro assay 
Bone marrow derived dendritic (BMDC) cells were differentiated in vitro using 
standard protocol39. Differentiated DC were harvested for stimulation after 6-
10 days. Bulk lymph node cells or sorted cells from C57BL/6 Foxp3EGFP 
reporter mice were labelled with PKH26 (sigma, PKH26GL) and incubated 
alone or together with sorted CD19+ B cells or BMDC in 2-5% FCS IMDM. IL-
2 supernatant or anti-IL-2 (S4B6) 10 µg/ml was added when indicated. 
Proliferation was monitored by measurement of PKH26 fluorescence in FL2 
channel using a FACS calibur. 
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Immunizations 
To induce a T-dependent antibody response, mice were injected 
intraperitonealy with 50µg NIP-ovalbumin in 200µl Alum. Sera were obtained 
from tail bleeding prior to and 14 days after immunization and stored at –
20°C. Total and hapten-specific IgG levels were determined by enzyme-linked 
immunosorbent assay (ELISA)10. 
 
GvHD exeriment 
GvHD was induced by intravenous injection of pooled cells suspension form 
lymnode and spleen cells from C57Bl/6 into (C57Bl/6 x DBA/2)F1. Animals 
were followed on a daily basis and euthanized when necessary. 
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Results 
Changes in T lymphocytes subsets following FLT3L treatment. 
The effect of increased FLT3L availability on dendritic cells (DC) development 
in mice is well documented4-9,40, however, little is known about the direct or 
indirect impact of prolonged FLT3L treatment on T cell populations. In order to 
study the influence of FLT3L levels on T cell populations, WT mice were 
injected daily with 10µg/day of recombinant cytokine for 10 days and 
compared with WT control and FLT3L knock-out (k.o.) mice6. Figures 1A and 
B show the percentages and absolute numbers of the indicated splenic 
subpopulations in FLT3L k.o., WT control or WT treated mice. Proportionally, 
changes in FLT3L level had the most striking effect on conventional DC 
(FLT3L k.o.: 0.1x106; WT: 1.7x106; WT Treated: 31x106) and plasmacytoid 
DC (FLT3L k.o.: 0.02x106; WT: 0.7x106; WT Treated: 10.6x106) as well as NK 
cells number (FLT3L k.o.: 1x106; WT: 3.3x106; WT Treated: 13.4x106) as we 
already reported previously10. Expansion of the DC compartment was also 
observed in the bone marrow, thymus and lymphnodes of treated mice (data 
not shown). Despite the differences of NK and DC numbers, the absolute 
numbers of CD4 or CD8 T cells were not drastically altered by changes in 
FLT3L levels (Figure 1B) and entire thymopoiesis was similar between control 
and treated mice (data not shown). We observed a decrease in B cell number 
in FLT3L k.o. compared to WT mice, which is due to decreased number of B 
cell precursors in the bone marrow (data not shown). 
The role for DC in extrathymic development of Tregs has been reported by 
many groups 23-26,41. Therefore, we wondered whether the influence of FLT3L 
level on DC numbers would have any influence on NTreg population. 
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Variations of FLT3L concentration had no influence on the percentage or the 
absolute number of NTreg cells in the thymus (Figure 1C). However there was 
a significant, dose-dependent increase in percentage and absolute number of 
Foxp3+ NTregs in the spleen (Figure 1D). Amongst CD4 T cells, FLT3L k.o. 
had 2 fold less Treg than WT mice (6.7% vs 12.8%) and in the best case 
FLT3L treatment increased Treg cells by 2 fold (12.8% vs 24%). Both DC and 
NTreg numbers went back to normal values after stopping FLT3L treatment 
(data not shown).  
Because the total CD4 T cells number in FLT3L k.o., WT or treated mice was 
similar (Figure 1B), we conclude that FLT3L level correlates with NTreg 
population size in the periphery but not in the thymus. 
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Figure 1. Influence of FLT3L treatment on lymphocyte subpopulations. 
C57BL/6 mice were injected intraperitoneally daily for 10 days with different dose of 
recombinant FLT3L. (A) Percentages of indicated splenic subpopulations in FLT3L k.o., WT 
control or WT treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in 
FLT3L k.o., WT control or WT treated mice. (C) Percentages of Foxp3+ cells among CD4sp 
(upper) or absolute numbers of Foxp3+ cells (lower) in thymus of FLT3L k.o., WT control or 
WT treated mice. (D) Percentages of Foxp3+ cells among CD4 T cell or absolute numbers of 
Foxp3+ cells in spleen of FLT3L k.o., WT control or WT treated mice. 
Each Bars shows mean +/- standard error of the mean. *, p<0.05; **, p<0.01.  
FLT3L k.o., light grey; WT control, grey; WT treated dark grey and black. 
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Origin of Treg increase 
Several non-exclusive mechanisms could explain the increase in NTreg after 
repetitive FLT3L injections. Firstly, we addressed the question whether the 
extra number of peripheral Tregs was due to enhanced thymic NTreg 
production.  Although we could not observe an increase in CD4SP Foxp3+ 
thymocytes (Figure 1C), FLT3L could potentially increase the rate of Treg 
development and output from the thymus. Therefore mice were 
thymectomized prior to FLT3L treatment. We observed that even in the 
absence of thymic output, there was still a FLT3L-dependent increase in the 
percentage and absolute numbers of splenic Treg cells (Figure 2A). This 
increase was comparable to that observed in non-thymectomized mice 
(Figure 1A), implying that the thymus does not contribute significantly to the 
increase in peripheral Ntreg. 
Thus, if peripheral NTreg expansion was thymus independent, it could be due 
either to i) the conversion of a CD4 T helper, non-Treg cell to a Treg 
phenotype and/or ii) the proliferation of pre-existing Treg upon increased 
FLT3L availability. To address the first hypothesis, we investigated whether 
CD4+ Foxp3- cells could become Foxp3+ upon FLT3L treatment. For this 
purpose, we injected 2x106 sorted CD4+Foxp3- CD45.2 cells from 
Foxp3EGFP reporter mice 38 into lightly (100rad) irradiated CD45.1 hosts and 
two weeks later, treated mice with FLT3L for 10 days or left them as control. 
As shown in figure 2B, treatment induced a significant increase in total Treg 
cells but did not induce Foxp3 expression in transferred cells (Figure 2C). We 
therefore conclude that FLT3L-mediated Treg increase was not due to 
conversion of effector to regulatory cells.  
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To challenge the second hypothesis, we determinated NTreg proliferation 
upon FLT3L treatment by the expression of the proliferation-associated 
marker Ki67. As shown in figure 2D, FLT3L treatment significantly increased 
the percentage of Ki67+ CD4+Foxp3+ and, to a lesser extent CD4+Foxp3-, in 
a FLT3L dose-dependent manner. This strongly suggests that FLT3L 
treatment induced a preferential increase proliferation of regulatory versus 
effector cells.   
Taken together, these results show that expansion of the peripheral NTreg 
compartment is due to proliferation of  NTreg cells upon FLT3L treatment. 
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Figure 2. Expansion of peripheral Treg compartment due to increased 
proliferation of Foxp3+ CD4 T cells. 
(A) Mice were thymectomized prior to FLT3L treatment (10µg intraperitoneal injection daily for 
10 days). Histograms show percentages of Foxp3+ among CD4 T cells (left) and absolute 
numbers (right) in the spleen of control or treated mice. Each bars shows mean +/- standard 
error of the mean. **, p<0.01. (B, C) CD45.1 WT mice were irradiated (100rad) prior to 
intravenous  injection of 2x106 sorted CD4+Foxp3- cells from CD45.2 Foxp3EGFP reporter 
mice. After two weeks, mice were treated with FLT3L (10µg intraperitoneal injection daily for 
10 days) or left as control. (B) Absolute numbers of CD4+Foxp3+ cells in the spleen of control 
or treated mice. Histogram shows mean +/- standard error of the mean. *, p<0.05.  (C) Foxp3 
expression in CD45.2+CD4+ donor cell population. (D) Histograms show percentages of Ki67 
positive cells among Foxp3+ (upper panels) or Foxp3- (lower panels) CD4 T cells in control or 
treated animals. 
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Dendritic cells support Treg proliferation 
FLT3L-induced Treg proliferation could be due either to a direct signalling of 
the cytokine on the Treg population or to an indirect effect. Since neither CD4 
helper nor Treg cells express detectable FLT3 at protein level (data not 
shown), we favoured the hypothesis of an indirect effect.  
FLT3L treatment increased both NK and DC numbers in the spleen (Figure 
1A-B). FLT3L-induced expansion of NTreg took place even when mice were 
depleted of NK cells by injection of anti NK1.1 mAb (data not shown), 
suggesting that NK cell were not instrumental in the expansion of NTreg cells.  
Given their ability to stimulate T cells, DC were the most plausible candidates 
responsible for the expansion of NTreg, We therefore addressed the capacity 
of DC to induce NTregs proliferation. As there is no simple, reliable, in vivo 
model available for long-term DC depletion, we addressed this hypothesis in 
vitro. 
Figure 3A shows the proliferation of NTreg and CD4 helper cells as measured 
by PKH26 staining. Neither CD4 helper nor NTreg cells proliferated alone (not 
shown) or in the presence of purified syngeneic B cells (Figure 2Aii). In 
contrast, co-culture with syngeneic in vitro FLT3L-induced bone marrow-
derived dendritic cells (BMDC) 39 led to a preferential proliferation of Foxp3+ 
cells (Fig 2Aiii). Cell division in these cultures was IL-2-dependent since it 
could be inhibited by addition of blocking anti-IL-2 antibody (Figure 2Aiv). 
Proliferation took place in the absence of any extra FLT3L and could not be 
blocked by addition of blocking anti-FLT3 antibody, again suggesting that 
there is no direct link between FLT3L and NTreg proliferation (data not 
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shown). Addition of blocking anti-TGFβ mAb in co-culture had no effect and 
sorted CD4+Foxp3- cells did not convert to a regulatory phenotype when 
incubated together with BMDC (data not shown), ruling out any conversion 
mechanisms as demonstrated in vivo (Figure 2B).  
Sorted NTreg proliferated only when they were cultured in presence of extra 
IL-2 and BMDC (Figure 3Biv), whereas IL-2 (Figure 3Biii) or BMDC (Figure 
3Bii) alone only induced a weak proliferation. These results argue firstly that 
neither BMDC nor NTreg produce IL-2 and secondly that NTreg need a DC-
mediated additional signal in order to proliferate in the presence of IL-2. This 
additional signal required direct cell-contact, since Treg did not divide 
significantly when they were incubated separately from BMDC in a transwell 
cultures (Figure 3Di) compared to cells incubated in direct contact with BMDC 
(Figure 3Dii). 
We next investigated whether CD4 helper and/or CD8 T cells were providing 
IL-2 to Treg cells. As shown in Figure 3C, sorted Tregs proliferated in the 
presence of BMDC plus CD4 helper or CD8 (Figure 3Ci-ii) and this 
proliferation could be inhibited by addition of blocking anti-IL-2 antibody 
(Figure 3Ciii-iv). This demonstrates that, unlike BMDC (Figure 3B), both CD4 
helper and CD8 T cells can provide IL-2 in these settings. 
We show here that unlike B cells, BMDC induce NTreg proliferation. 
Proliferation was IL-2 dependent and required an additional cell-contact 
dependent signal supplied by DC.  
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Figure 3. FLT3L-differentiated bone marrow-derived dendritic cell induce 
proliferation of Treg. 
(A) PKH26-labeled lymph node cell suspension from Foxp3EGFP reporter mice were 
incubated with sorted syngeneic B cell or syngeneic in vitro FLT3L-differentiated BMDC for 5 
days with or without antagonistic anti-IL-2. Dot plots show PKH level on CD4 T cells. (B) 
PKH26-labeled CD4+Foxp3+ cell sorted from Foxp3EGFP reporter mice were incubated  with 
or without extra IL-2 and with or without BMDC. Histograms show PHK26 level on 
CD4+Foxp3+ cells after 5 days of incubation. (C) PKH26-labeled CD4+Foxp3+ cell sorted 
from Foxp3EGFP reporter mice were incubated with BMDC and sorted CD4+Foxp3- 
(CD4:Treg, ratio 4:1) or CD8+ (CD8:Treg, ratio 2:1) T cells. Co-culture were done in presence 
or absence of antagonistic anti-IL-2. Histograms show PHK26 level on CD4+Foxp3+ cells 
after 5 days of incubation. (D) PKH26-labeled CD4+Foxp3+ cell sorted from Foxp3EGFP 
reporter mice were incubated with extra IL-2 only (empty histogram) or with BMDC without 
(left panel) or with (right panel) contact. Histograms show PHK26 level on CD4+Foxp3+ cells 
after 5 days of incubation. 
88
                                
  
DC mediated Treg expansion is TCR-independent. 
We concluded from figure 3B that IL-2 was necessary but not sufficient to 
induce sustained NTreg proliferation in vitro and we postulated that BMDC 
were providing a second signal, which was enhancing Treg proliferation. A 
strong TCR signal together with CD28 co-stimulation is known to induce 
NTreg proliferation in vitro in the presence of extra IL-2, hence we looked to 
see whether DC-induced Tregs proliferation was TCR dependent. As shown 
in figure 4A, MHC class II k.o. BMDC 37 were as potent as WT BMDC in 
inducing the proliferation of sorted NTreg when extra IL-2 was provided. This 
argues that DC induced NTreg proliferation is independent of TCR-MHC class 
II interactions. Since sorted NTreg cells did not proliferate when stimulated 
with plate bound anti-CD28 plus IL-2 (data not shown), we conclude that 
BMDC were inducing NTreg proliferation by a TCR-independent CD28-
independent mechanism.   
Next we wondered whether FLT3L treatment would induce Treg expansion in 
the absence of TCR-MHC class II interactions in vivo. To test this hypothesis, 
we lethally irradiated WT mice and reconstituted them with bone marrow from 
MHC class II k.o.. In such chimeras, MHC class II molecules are still 
expressed on radio-resistant cells of the thymus, allowing CD4 T cells to 
develop, but are completely absent on radiosensitive cells. As expected, in 
these chimeras, CD4SP and mature CD4 T cells could be found in the thymus 
(Figure 4B) and spleen (Figure 4C). In the spleen, MHC class II expression 
could not be detected either by FACS (Figure 4D) or by immuno-histology 
(data not shown). As expected, FLT3L treatment led to an increase in the 
number of dendritic cells and had no influence on the expression of MHC 
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class II in the spleen (Figure 4E). FLT3L induced an increase both in the 
percentage and absolute number of NTreg (Figure 4F-G). 
Taken together, we conclude that MHC class II-TCR interactions are 
dispensable for DC induced Treg proliferation both in vitro and in vivo. The 
nature of the second signal delivered by DC, which is necessary for enhanced 
Treg proliferation is still under investigation. 
 
Figure 4. Mechanism of FLT3L-induced Treg proliferation is TCR-
independant. 
(A) PKH26-labeled CD4+Foxp3+ cell sorted from Foxp3EGFP reporter mice were incubated 
with WT BMDC (filled histogram, left panel), MHC class II k.o. BMDC (filled histogram, right 
panel) or alone (empty histogram) in presence of extra IL-2. Histograms show PHK26 level on 
CD4+Foxp3+ cells after 5 days of incubation. (B-G) WT mice were lethally irradiated and 
reconstituted with MHC class II k.o. bone marrow. (B) CD4 versus CD8 expression in thymus 
of MHC class II k.o. -> WT chimera. (C) CD4 versus CD3 expression in spleen of MHC class 
II k.o. -> WT chimera. (D, E) MHC II expression in the spleen of control (C) or FLT3L-treated 
(D) MHC class II k.o. -> WT chimera (black line) versus WT control (grey line). (F, G) 
Percentages of Foxp3+ cells among CD4 T cell or absolute number of Foxp3+ cells in spleen 
of treated vs control MHC class II k.o. -> WT chimera. Each histogram shows mean +/- 
standard error of the mean. *, p<0.05. 
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FLT3L treatment does not impair normal immune response but can 
prevent mice dying from by acute Graft versus Host disease. 
We wondered what would be the influence of increasing the number of DC 
and NTreg by FLT3L treatment on a T-dependent antibody response as well 
as in a GvH model. As showed in figure 5A, FLT3L treatment had no influence 
on an anti-NIP antibody response as measured by ELISA for specific Ig. Both 
control and treated animals had similar titres of anti-NIP antibody following 
immunisation. However, as it was reported previously 40, FLT3L treatment 
completely prevented death due to acute GVHD caused by injection of 
C57Bl/6 lymphocytes into (C57Bl/6 x DBA/2)F1 animals (Figure 5B). FLT3L 
treatment could partially prevent death even when treatment was initiated 1 
week after disease induction (Figure 5B). In addition, FLT3L treatment 
protected mice from GvHD-induced death even when mice were depleted of 
NK cells by injection of anti-NK1.1 mAb at time of GvHD induction (data not 
shown), suggesting that, in accordance with previously published data40, NK 
cells had no role in FLT3L-mediated protection of GvHD. 
In conclusion, we show here that FLT3L treatment had no influence on an 
antibody response whereas it had a clear, beneficial effect in preventing death 
caused by acute GvHD. 
 
 
 
91
                                
  
 
Figure 5. FLT3L treatment does not impair normal immune response but 
can prevent mice dying from by acute Graft versus Host disease. 
(A) C57Bl/6 mice were treated with FLT3L (10µg intraperitonal injection daily for 10 days) or 
untreated. Mice were then immunized with 50µg NIP-OVA in Alum intraperitonealy.  Anti-NIP 
IgG titers were determined at day 0 and 14 by ELISA. (B) (C57Bl/6 x DBA/2)F1 were injected 
with 50 x 106 pooled Lymphnode/spleen from C57Bl/6 mice. Recipient mice were either kept 
as control, treated with FLT3L for 10 days prior to GvHD initiation (”pre-treatment”) or 1 week 
after (”post-treatment”). Curves show percentage survival of each group. 
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Discussion 
 
Factors controlling NTreg homeostasis are not yet completely understood, 
however it would seem that there is a niche of pre-determined size for the 
NTreg population. Thus the proportion of NTreg amongst total CD4 T cells is 
set early on during ontogeny and kept fairly constant until advanced adulthood 
42. This is also true regarding the proportion of NTreg in different mouse 
strains, the ratio between regulatory and effectors cells is varying significantly 
between strains but is very constant within each strain 43. Altogether, it 
strongly suggests that a combination of factors keep the NTreg niche to a 
given size in homeostatic conditions. Moreover, it seems that even in 
lymphopenic situation like in pTα or IL-7 deficient mice, the size of the NTreg 
compartment is preserved 44.   
The unique role of IL-2 in NTreg biology is well described and there is clearly 
a direct correlation between cytokine availability and NTreg numbers. In mice, 
increasing IL-2 availability by injection of highly potent IL-2/anti-IL-2 complex 
expand NTreg number in the periphery 45,46 whereas neutralizing IL-2 by 
injection of mAb induce a decrease in NTreg numbers and eventually leads to 
autoimmune disease due to absence of NTreg-mediated tolerance 47. Since 
IL-2 production by NTreg is minimal 48-50, they rely for their survival on IL-2 
produced by conventional CD4 helper cells 51.  
The role of CD28 signalling in thymic NTreg development has been dissected 
31, however its precise role in NTreg homeostasis in periphery is less clear. 
Although inhibition of CD28 by injection of blocking antibody leads to reduced 
numbers of peripheral NTreg 32, it is not completely understood to what 
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extent, this effect is NTreg intrinsic or due to a decrease in IL-2 production by 
CD4 effector cells caused by a lack of costimulatory signals. If injection of 
anti-CD28 “superagonist” antibody were reported to induce NTreg proliferation 
in vitro and in vivo 52, it does not mimic the physiological situation where CD80 
and CD86, the natural ligands of CD28, also bind to the inhibitory molecules 
CTLA-4. NTreg are also known to proliferate upon antigen encounter in vivo 
33-36 and in vitro; NTreg can be stimulated with antigen loaded APC 35,53. 
However, in homoestatic conditions, one can wonder what proportion of Treg 
receive such a strong TCR signal.  
So far, therefore the only reported ways of inducing NTreg proliferation have 
been either by TCR stimulation, increased IL-2 availability or CD28 co-
stimulation. However, in this report, we show that FLT3L treatment likely by 
increasing DC number also results in an increase in NTreg number. 
 
Thus repetitive FLT3L injections expanded peripheral Treg probably by 
favouring interactions between DC and NTreg. This increase in NTreg was 
not due to phenotypic conversion from conventional to NTreg cells (Figure 
2B). Moreover, FLT3L treatment had no influence on the CD103+ DC 
population (data not shown), which was recently reported to be particularly 
efficient at promoting extrathymic NTreg differentiation 26.   
We could show in vitro that DC control NTreg proliferation by cell-contact 
mechanisms in a TCR independent manner, allowing cells to divide in the 
presence of IL-2. Addition of blocking anti-TGFβ mAb had no effect on the 
outcome of the co-culture, suggesting again the absence of differentiation 
mechanisms. We can postulate that the signals delivered by DC is either 
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positively influencing the IL-2 signalling pathway and/or giving an independent 
additional signal. Since a) neither FLT3L treatment nor NTreg stimulation by 
BMDC had an effect on CD25 or IL-2Rβ expression by NTreg and that b) IL-2 
was not a limiting factor in our in vitro experiments, we rather think that DC 
provide an additional signal (or signals) to NTreg. This signal seems to 
determinate very clearly whether or not cells will enter cell cycle in the 
presence of IL-2 and explain the absence of sustained proliferation of sorted 
NTreg cells in the presence of saturating IL-2. These conclusions imply that 
the expansion we observe in vivo and in vitro is very likely to be polyclonal. It 
might guarantee polyclonality of the NTreg repertoire in homeostatic 
conditions and reciprocally to avoid oligoclonality in a situation where a 
considerable subpopulation of the NTreg is in constant presence of their 
cognate antigen 54. 
We suggest that DC play a privileged role in the control of the NTreg niche in 
the periphery. This is strengthened by several facts. Firstly, increasing DC 
numbers by, for example GM-CSF treatment, induces similar increases in 
NTreg numbers 55. Secondly, both DC and NTreg numbers go back to normal 
values shortly after DC numbers decrease after stopping FLT3L treatment 
(data not shown). Thirdly, in FLT3L k.o. mice, in which the most striking 
phenotype is the decrease in DC number (Figure 1B), there is a significant 
decrease in Treg number and percentage of CD4 T cell in the periphery only. 
Finally, the fact that Jh k.o. mice 56, which have no B cells, have comparable 
percentages of splenic NTreg compared to WT mice suggests that B cells, 
which represent the vast majority of splenic APC in normal mice, do not play 
any role in controlling the size of the peripheral NTreg niche. This last point 
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underlines the unique role of DC in setting the size of peripheral NTreg niche. 
Overall this might be a mechanism for the immune system to ensure 
equilibrium between the number of professional APC and the number of 
NTreg. Given their key role in T cell priming, it is probably necessary to keep 
a homeostatic link between DC and Treg, as it is the case for CD4 helper cells 
and NTreg.  
 
FLT3L treatment did not interfere with an antibody immune response, despite 
the increase of immature DC and Treg numbers (Figure 5A). We hypothesize 
that in the presence of a strong adjuvant, most of the DC induced by FLT3L 
treatment will mature and will therefore have a positive impact rather than 
tolerizing effects on immune response. In such a situation, it would not be 
surprising that increasing the number of NTreg had no effect on the final 
immune response.   
In contrast, the effect of FLT3L treatment on GvHD outcome was very 
dramatic. When FLT3L injections were performed prior to GvHD initiation, 
treatment could rescue 100% of mice. Strikingly, up to 60% of mice could be 
rescued when treatment was started 1 week after GvHD induction. We 
conclude from the latter results that FLT3L treatment is able to stop or 
decrease GVHD even after allo-T cell priming, suggesting that the mechanism 
of tolerance involved are likely to be dominant. In some situation of GvHD, 
recipient NK cells can reject donor cells; a mechanism called “hybrid 
resistance”. We therefore wondered if FLT3L treatment was enhancing 
rejection of allo-T by increasing the number of NK cells. However, we could 
exclude a role for NK cells. It was reported that FLT3L-mediated protection 
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was due to increased numbers of immature DC and that in vitro, DC from 
FLT3L-treated animals were far less potent in allo-T cell priming compared to 
DC from control animals 40. Although we agree with these conclusions, we 
think in addition that it is not the only way by which FLT3L treatment protects 
from GvHD. We have previously shown that Treg transfer can prevent death 
from syngeneic GvHD after bone marrow transplantation 57 and others have 
demonstrated the importance of Treg in allograft acceptance 58. Therefore we 
think that FLT3L might prevent death due to GVHD partly by increasing the 
number of NTreg as well as immature DC. 
We conclude that, by increasing both immature DC and Treg numbers, FLT3L 
treatment might be a very valuable way of improving GvHD or autoimmune 
disease outcome without impairing immune response.  
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ABSTRACT
It has been known for more than thirty years that in lethally irradiated bone
marrow chimeras, part of the reconstituted T cell compartment is derived from the
irradiated host. However, the detailed origin and functional activity of these host-
derived T cells has not been thoroughly analysed. Here, we generated bone marrow
chimeras by reconstituting lethally irradiated C57BL/6 mice with either syngeneic
Rag2-deficient or CD3-epsilon-deficient BM neither of which is capable of generating
T cells and therefore, all surviving T cells were exclusively host-derived. We show
that in the absence of donor-derived cells, host-derived T cells can reconstitute 35%
of the normal T cell pool. By comparing thymectomized versus non-thymectomized
host, we show that host-derived T cells, comprised a major (70%) subpopulation of
de novo generated, thymus-derived, polyclonal, naïve cells and a minor
subpopulation of surviving, peripheral, oligoclonal, memory-like cells. Host-derived
thymocytes regenerated from conventional DN1-2 prothymocytes and their
differentiation recapitulated normal thymic ontogeny. Thus, host-derived T cells might
provide a first line of defence against infections during recovery from lymphopenia
after BMT. This conclusion is supported by the fact that host-derived T cells were
fully functional.
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INTRODUCTION
In man, syngeneic or allogeneic bone marrow (BM) transplantation (BMT) with
BM donors is a frequently used treatment modality which has curative results for a
variety of haematological disorders such as malignant or genetic-based immune
deficiencies. Nevertheless, the restoration of an adaptive immune system (with both
B and T cells) in transplanted patients is a very slow process and during the initial
reconstitution phase, patients are lymphopenic. T cell recovery plays a key role in the
clinical recuperation of patients post-BMT as they lack adequate T cell-mediated
immunity: they often succumb to one of several life-threatening infections, especially
cytomegalovirus (CMV) infections (reviewed in (Gress et al., 2007; Hakim and Gress,
2005)). Roosnek and colleagues recently showed that the presence of residual host-
(surviving the conditioning regimen) or donor-derived (persisting and expanding from
the BM inoculum) CMV-specific CD8+ memory T cells could provide efficient anti-viral
immunity and help patients combat CMV infections in the lymphopenic period
following BMT (Chalandon et al., 2006). Therefore, in man, it seems that donor and
recipient immune infection history should be taken into account in designing the best
BMT protocol strategy including whether the donor BM should be T cell depleted and
how recipients should  be conditioned. The ability of patients, especially adults, to
regenerate T lymphocytes after BMT or conditioning therapy-related depletion of the
host mature T lymphocyte compartment has emerged as a critical problem in clinical
medicine. However, studies in man are difficult to control experimentally and animal
models are required to dissect and improve BMT outcomes.
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We and others have shown that host-derived T cells are present in lethally
irradiated mouse BM chimeras (Anderson et al., 2004; Benard et al., 2006; Komatsu
and Hori, 2007). However, the origin and function of these cells were not fully-
characterized. This prompted us to examine more carefully the host-derived T cell
pool in chimeric mice. We recently showed that host-derived T cells were enriched in
extra-thymically located, radio-resistant, functional CD4+CD25+ regulatory T cells
which could prevent a syngeneic graft-versus-host (GvH) disease following BMT
(Benard et al., 2006).
The object of the current study was to characterize further host-derived T cell
development and function in chimeric mice. To this end, we generated chimeras by
reconstituting lethally-irradiated C57BL/6 mice with either syngeneic Rag2-/- or
CD3ε-/- BM. In such chimeras, donor-derived BM progenitors are not able to generate
T cells and surviving T cells will be exclusively host-derived. We showed that host T
cells contain a mixture of de novo-generated naïve T cells and surviving peripheral
memory-like cells. We found that host-derived thymopoiesis was initiated by DN1-2
prothymocytes having a conventional (CD44high, CD117high, CD25-/+) phenotype and
we further demonstrate that T lymphopoiesis recapitulates normal thymic ontogeny
after BMT. Additionally, by comparing host-derived T cell numbers in non-
thymectomized (NTX) versus thymectomized (TX) hosts, we observed that the
differentiation of host-derived thymocytes provided an important cohort of naïve,
functional, mature T cells having a large TCR repertoire and accounting for up to
35% of the total T cell number found in a control chimeric or unmanipulated mice.
Moreover, by using TX hosts, we could show that there was a second population of
extra-thymically located, CD44highCD62L- memory-phenotype, functional T cells
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having an oligoclonal TCR repertoire. These host-derived T cells might provide a first
line of defence against infections during recovery from lymphopenia after BMT.
RESULTS
1. Host-derived T cells following BMT in lethally-irradiated mice.
More than 30 years ago, it was already recognised that in lethally irradiated
BM chimeras, part of the T cell compartment was of host origin (Ceredig and
MacDonald, 1982; Hirokawa et al., 1985; Kadish and Basch, 1975; Lesley et al.,
1990; Sharrow et al., 1983). However, the precise origin and functional activity of
these host-derived T cells has not been thoroughly analysed. In order to study host-
derived lymphocytes, we reconstituted lethally-irradiated C57BL/6 CD45.2 mice with
T-cell depleted (TCD) BM from C57BL/6 CD45.1 donors. After six months, to
characterise the host- and donor-derived lymphoid compartments of chimeric mice,
we stained splenocyte suspensions with combinations of CD45 allotype-specific
antibodies, CD3 for T cells, and CD19 for B cells and analysed them by FACS. As
expected, in these syngeneic bone marrow transplantation (BMT) experiments, all
recipient mice survived (10/10) indicating a good BM engraftment and there was no
evidence of Graft-vs-Host disease (GvHD). However, a sizeable host-derived
CD45.2+ lymphocyte population survived even as long as 6 months after BMT. Host-
derived lymphocytes in chimeric mice were exclusively CD3+ and represented about
5% total splenic T cells (Figure 1A). Importantly, the absence of host-derived CD19+
B cells ruled out the possibility that host-derived multi-potent cells had survived in our
chimeras; this was further confirmed by analysis of the BM where all progenitor
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compartment were donor-derived (data not shown). Additional phenotypic analysis of
host-derived T cells showed that both CD4+ and CD8+ cells were present and that
they were enriched in CD44high CD62L+/- cells compared with their donor-derived
partners (Figure 1B). Thus, host-derived T cells are still present in chimeric mice and
are mostly composed of CD44high memory-like cells (Tough and Sprent, 1994). To
evaluate whether host-derived T cells could be found in other locations, we studied
lymphocytes isolated from the blood, gut, liver, lung, lymph nodes and skin of
chimeric mice 6 months after reconstitution. Again, none of these organs contained
host-derived B cells (data not shown) but did contain host-derived T cells in different
proportions. As shown in figure 1C, about 3-5% of blood, LN and spleen, and 10-20%
of gut, liver, lung and skin CD3+ T cells were host-derived. Together, these data
revealed the presence of a substantial pool of host-derived mature T cells in chimeric
mice despite lethal irradiation preceding BMT.
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Figure 1. Host-derived T cells are present in lymphoid and peripheral organs of
mouse BM chimeras. (A) Lethally-irradiated C57BL/6 CD45.2 mice were reconstituted with T-
cell depleted (TCD) BM from C57BL/6 CD45.1 donors. After six months, splenocyte suspensions were
stained for CD3, CD19 and CD45 allotype. A typical result of FACS analysis is shown. CD3+ T cells
and CD19+ B cells were gated as shown in left dot-plot and the proportion of CD45.2+ (host-derived
cells) was quantified as shown in the right histograms (N.D., not detected). (B) In the upper dot-plots,
shown are CD4 and CD8 distribution in splenocytes. In the middle and lower dot-plots data shown are
CD44 and CD62L expression on gated CD4+ (middle dot-plots) or CD8+ (lower dot-plots). Cells were
either CD45.1+ donor-derived (left dot-plots) or CD45.2+ host-derived (right dot-plots). Shown in A-B
are representative results of 5-10 mice analyzed. Numbers in the quadrants indicate percentages of
cells. (C) T cell chimerism in blood (Bl.), gut, liver (Liv.), lung (Lu.), lymph nodes (LN), spleen (Spl.)
and skin (Sk.) was analysed. Bar histogram represents the mean ± SD of host-derived T cells
(CD3+CD45.2+) from 3-5 mice.
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2. Following BMT most host-derived T cells are derived from a single wave of
thymic T cell differentiation.
Multiple origins could explain the persistence of host-derived mature T cells in
chimeric mice. Firstly, host-derived T cells progenitors could survive and generate T
cells. These progenitors could reside either within the thymus or elsewhere and
generate either thymus-derived T cells or extrathymic-derived T cells respectively.
Secondly, some host-derived mature T cells could represent radio-resistant, resident
T cells. These hypothesis are not mutually-exclusive and to discriminate between
them, we generated several chimeric mouse combinations as described below.
To demonstrate that the host thymus is still able to produce T cells following
lethal irradiation and BMT, chimeras were generated by reconstituting lethally
irradiated C57BL/6 mice with C57BL/6.Rag2-/- BM. In such chimeras, donor-derived
BM progenitors are not able to generate T cells and surviving T cells will be
exclusively host-derived. We tracked host-derived T cells in the thymus and spleen
from 1 to 6 weeks following BMT. The total number of thymocytes rapidly decreased
and reached about 2 x 106 cells one week post-BMT. Reduction of cell number
occurred in each CD4 and CD8-defined thymocyte subset, but the degree of
reduction varied among the subsets, possibly reflecting their relative radio-sensitivity
(CD4+CD8+ double positive (DP) > CD4+CD8- or CD4-CD8+ single positive (SP)).
Figure 2A shows the changes in proportion of each T cell subsets in thymus and
spleen. As reported by others (Penit and Ezine, 1989), DP thymocytes are highly
susceptible to irradiation and, in the first week following BMT, decreased rapidly from
89.6% in control un-irradiated mice to 3.3%. In contrast, at one week post-BMT, we
observed a relative enrichment of CD4+ SP cells, representing 73.2% of total
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thymocytes whereas they represented only about 10% of thymocytes in control mice.
At two weeks post-BMT, thymocyte number had increased to reach a maximum of 45
x 106 cells, representing about 50% of control thymus cellularity. At that time, the
CD4 and CD8 distribution was very similar to controls.  Additionally, phenotypic
analysis revealed that SP thymocytes in chimeric mice were indistinguishable from
controls, expressing high level of CD3 and TCRβ, and about 5% of CD4+ SP cells
were FoxP-3+ (data not shown). At six weeks, thymus cellularity had decreased to
less than 1 x 106 cells. At this time, the thymic rudiment contained exclusively host-
derived SP cells.
In the spleen of these chimeras, results reflected what we observed in the
thymus. Thus, as early as one week post-BMT, there was a dramatic loss of
cellularity and spleens contained a mean of only 10.8 x 106 cells. CD4+ T cells
represented almost all radio-resistant T cells. At 2 weeks post-BMT, splenocyte
number peaked at 17.1 x 106 cells, finally decreasing to ~8-10 x 106 cells at 6 weeks.
Throughout this time, the numbers of CD4+ T cells exceeded that of CD8+ T cells.
The percent CD4+ T cells at 1, 2 and 6 weeks post-BMT were 8.5, 2.9 and 39.8
whereas those of CD8+ cells were 1.1, 1.4 and 6.7 respectively. Interestingly and as
already documented by others, host splenocytes contained about 0.4 % DP cells; this
could reflect some degree of so-called extra-thymic T cell differentiation (Allman et
al., 2001; Antica and Scollay, 1999; Garcia-Ojeda et al., 1998; Terra et al., 2005).
Thus, as we (Ceredig and MacDonald, 1982) and others (Kadish and Basch, 1975;
Penit and Ezine, 1989; Sharrow et al., 1983) have previously shown, following lethal
irradiation and BMT, a single wave of host-derived reconstitution occurred (herein
referred as auto-reconstitution), but the nature of the radio-resistant T cell precursors
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responsible for this remained undefined. Additionally, we observed a significant
number of mature T cells in the periphery as long as 6 weeks post-BMT. It should be
noted that this pool of host T cells could comprise a mixture of (i) radio-resistant
mature peripheral T cells that had survived and expanded (ii) T cells derived de novo
from the host thymus and (iii) some not well-characterized T cells generated via
extra-thymic differentiation.
Next, to clarify the relative contribution of these processes to the host-derived
T cell pool, we generated chimeras where C57BL/6.CD3ε-/-.CD45.1 BM was
transferred into lethally irradiated C57BL/6.CD45.2 hosts which were either
thymectomized (referred herein as TX) or not thymectomized (referred herein as
NTX). In these chimeras, all mature T cells would be host-derived with those in TX
recipients being of only extra-thymic origin and those in NTX recipients a mixture of
extra-thymically and thymus-derived cells. Thus, the difference in T cell numbers
between these two groups of chimeras would reveal the contribution of thymic-
derived T cells to the overall pool. As shown in figure 2B, the donor-derived B cells in
the spleen of NTX and TX were very similar to controls and represented 50-60 x106
cells or 70-87% splenocytes respectively 2-3 months post-BMT. In contrast, the
mean number of host-derived T cells was about 20 x106 in control chimeras,
decreasing to ~7 x106 cells in NTX and to only about 2 x106 cells in TX chimeras.
Thus, in the spleen, 5 x106 host-derived T cells were thymus-derived whereas only 2
x106 were from an extra-thymic origin. In TX chimeras, histological analysis of spleen
sections revealed abnormal follicular architecture with small, scattered, T cell areas
reflecting their severe lymphopenia. In contrast, spleen sections from NTX animals
displayed normal features (figure 2C). Our results show that (i) in chimeras where all
T cells are host-derived, about 35% [(7/20) x100] of the normal T cell pool could be
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formed and maintained and (ii) more importantly, at least 71% [100 – (2/7 x100)] of
host-derived T cells are derived from the thymus. This value may be an
underestimate because it assumes that the extra-thymically derived T cell pool
remained constant in TX versus NTX recipients.
Figure 2. Host-derived T cells in lethally irradiated chimeras are mainly coming
from a transient wave of T cell differentiation within the thymus. (A) Lethally-
irradiated C57BL/6 mice were reconstituted with total BM from C57BL/6.Rag2-/- donors. Thymus and
spleen were analyzed at week 1, 2 and 6 post-BMT. Shown are CD4 versus CD8 staining on viable
lymphocyte gate. Numbers on the top of the quadrants and in the quadrants indicate mean organ cell
numbers ± SD and percentages of cells respectively. (B) Lethally-irradiated C57BL/6.CD45.2 mice
were thymectomized (TX) or not (NTX) and reconstituted with BM from C57BL/6.CD3ε-/-.CD45.1
donors. Chimeras were analyzed 8-12 weeks post-BMT. Bar histograms represent total B (black bars)
and T (white bars) lymphocyte numbers ± SD (n=10) in controls and chimeras. , P <0.01. (C)
Frozen spleen sections from chimeras described in figure 2B were prepared and stained as described
in materials and methods. B cells appear in red and T cells in green. Scale bar, 100 µm.
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3. Thymus-derived host T cells originate from radio-resistant DN1-2 like
thymocytes.
The above results demonstrated that most (>70%) host-derived mature T cells
were derived from a single wave of thymocyte differentiation. The presence of a host-
derived thymocyte precursor has been proposed (Ceredig and MacDonald, 1982;
Kadish and Basch, 1975; Penit and Ezine, 1989; Sharrow et al., 1983), however,
whether it is an intra-thymic “classical” progenitor or an “atypical” cell was not
resolved. Indeed, it had been proposed recently (Maillard et al., 2006) that
reconstitution of the thymus in the BM chimeras was derived directly from an
“atypical” CD25+CD44-CD117- DN3-like precursor. Therefore, complementary
approaches were undertaken to further characterise host-derived thymocyte
precursors.
As host-derived mature lymphocytes were almost exclusively T cells, we
concluded that this radio-resistant precursor should reside within the thymus where T
cell precursor commitment is thought to take place. In order to demonstrate that a
pool of intra-thymic T cell precursors survive lethal irradiation and can differentiate
into mature thymocytes, we carried out foetal thymus organ culture (FTOC)
experiments with foetal thymus lobes from lethally irradiated pregnant mice. As
shown in figure 3A (and data not shown), one week after FTOC, irradiated thymi
contained TCRβ+ DP and SP cells in a proportion similar to that of controls. The
same experiments were carried out with pieces of adult thymus in organ culture
(ATOC). Again, we observed typical signs of thymocyte differentiation and despite
lethal irradiation, organ-cultured adult thymi contained TCRβ+ DP and SP cells one
week after ATOC (data not shown).
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Next, C57BL/6 mice were reconstituted with Rag2-/- BM and treated with anti-
IL-7Rα mAb immediately after BMT (figure 3B, right graph). At two weeks post-BMT,
following anti-IL-7R α treatment, the number of host-derived T cells was greatly
diminished with thymocyte cellularity reduced from ~50 to 1 x 106 cells. This
reduction in cellularity was associated with a block of DN to DP stage transition
(figure 3B, left panels). We conclude that some T cell precursors survive lethal
irradiation, reside within the thymus and that their differentiation is IL-7 dependent.
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Figure 3. Radio-resistant DN1-2 thymocyte precursors reside in the thymus
following lethal irradiation. (A) Shown are the CD4 versus CD8 profiles of day-7 FTOC with
(right) or without (left) lethal irradiation (950 cGy) at day 0. Numbers in the quadrants indicate
percentages. Shown is one representative experiment out of 5 conducted independently. (B) The
same chimeras as in figure 2A were done and following BMT either injected i.p. with 300 µg of anti-IL-
7R blocking antibody (A7R34) in 200 µl of PBS once a week (treated) or with PBS only (sham). Two
weeks post-BMT, mice were killed and their thymus analysed by FACS. Shown are CD4 versus CD8
profiles (left dot-plots) and mean thymocyte numbers ± SD (n=3) in a logarithmic scale (right histogram
bars). , P <0.05.
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The properties of these thymocyte progenitors were reminiscent of those of
typical DN1-2 thymocyte precursors (Balciunaite et al., 2005; Balciunaite et al., 2005;
Ceredig and Rolink, 2002). We therefore enriched DN cells from C57BL/6.CD45.1 
C57BL/6. CD45.2 chimeric mice from 1 to 3 weeks post-BMT and by CD44 and
CD117 staining, we were able to reveal the presence of CD44+CD117high cells
corresponding to ~0.3 to 0.6% of DN preparations (Figure 4A, left dot plots). As
shown in figure 4A, this population contained CD117high DN1 (CD44+CD25-) and DN2
(CD44+CD25+) T cell precursors. We then quantified the host- and donor-origins of
DN1 and DN2 cells from chimeras 1 to 3 weeks post-BMT (Figure 4B, bar graphs). At
1 week post-BMT, DN1-2 cells were detected which were ~99% host-derived and this
proportion decreased to ~90% at 2 weeks and finally to less than 1-5% at 3 weeks
post-BMT. Thus, early “classical” T cell progenitors exist in the thymus of chimeric
mice even though they are rare cells. Initially, the CD117high progenitor compartment
is almost exclusively host-derived but later gets diluted by donor-derived cells.
We next addressed the T-cell development potential in vitro of host-derived
thymic CD44+CD117high cells found in chimeric mice at week 1 post-BMT. About
2x103 cells were sorted and differentiation potential was assessed by plating them on
OP9-DL1 stromal cells (supporting T-lineage development) in the presence of IL-7.
Cells expanded rapidly, reaching about 105 cells one week after culture when they
were harvested and analyzed by FACS. They underwent typical T-lineage
development features by up-regulation of CD25 and down regulation of CD44
expression (figure 4C left dot-plot). One week post-BMT, 95% of the cells were
CD45.2+ host-derived (figure 4C right histogram). Taken together, our results
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characterize for the first time the nature of genuine radio-resistant T cell precursors.
These cells are (i) intra-thymic in location, (ii) grow in an IL-7-dependent fashion, (iii)
display a normal CD117high phenotype and (iv) are functional bona-fide DN1-DN2
cells with canonical T cell developmental potential.
Figure 4. Radio-resistant DN1-2 thymocytes recapitulate normal thymic
ontogeny in vitro. (A) Lethally-irradiated C57BL/6.CD45.2 mice were reconstituted with TCD BM
from C57BL/6.CD45.1 donors. Thymi were analyzed at week 1, 2 and 3 post-BMT. Shown in the right
are CD44 versus CD117 on DN preparation and CD44 versus CD25 staining on gated
CD44+CD117High cells from an unmanipulated control or a chimeric mouse. CD44+CD25- and
CD44+CD25+ represent DN1 and DN2 respectively. Numbers in the quadrants indicate representative
percentages. (B) Bar histograms display the kinetics and mean numbers (n= 3-5 mice for each time
point) of host- and donor-derived DN1 and DN2 cells in black and white respectively from 1 to 3 weeks
post-BMT.  (C) The same chimeras as described in figure 4A were done, 5 mice were killed pooled
and used to sort CD44+CD117High DN1 and DN2 cells one week after BMT. About 2000 cells were
plated on OP9-DL1 stroma with IL-7 and analysed by FACS 7-10 days later to assess their in vitro T-
cell development potential. Shown are CD44 versus CD25 profiles and CD45.1 (donor-derived) or
CD45.2 (host-derived) proportion of recovered thymocytes.
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4. Host-derived T cells are functional, but presence of the thymus is required to
ensure an unbiased TCR repertoire
A series of chimeras comparing NTX and TX hosts were generated and
analysed further to evaluate the functional importance of the thymus in auto-
reconstitution. Phenotypically, the most notable difference between the two
subpopulations was the increased proportion of naïve (CD44lowCD62L+) T cells in
NTX hosts (17% and 11.8% for CD4+ and CD8+ T cells respectively) compared with
TX hosts (1.8% and 2.3% for CD4+ and CD8+ T cells respectively) (Figure 5A). In
controls (un-manipulated or B6B6 chimeras), most T cells displayed a naïve
phenotype with 66.8% and 46.2% of CD4+ and CD8+ T cells respectively (Figure 5A
left panels) having the CD44lowCD62L+ phenotype. Thus, NTX chimeras contained a
higher proportion of memory phenotype (CD44HighCD62L-) T cells whereas in TX
chimeras almost all T cells were of this phenotype.
The reduced T cell number in TX hosts, where T cells are only extra-thymically
derived combined with their severe T cell lymphopenia might result in a repertoire
bias and a consequent functional defect. To investigate the repertoire question
further, we stained T cells from 10 mice from each group of chimeras with a panel of
anti-TCR Vβ-specific mAbs. As shown in Figure 5B, the TCR Vβ repertoire of CD4+
and CD8+ T cells in NTX chimeras consistently resembled that found in controls. This
was in clear contrast to that of TX chimeras where in many mice the TCR Vβ
repertoire was frequently biased.
Next, to determine if TX hosts had functional defects, we measured their ability
to mount a T-dependent (TD) antibody response. As shown in figure 5C, 14 days
following NIP-OVA immunisation, NTX chimeras were able to mount a TD antibody
response as efficiently as controls. This was in striking contrast to TX chimeras,
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where only 4 out of 10 mice were able to mount a TD immune response. Taken
together, our results show that host-derived T cells in chimeras are functional but in
TX hosts, their oligoclonal nature frequently resulted in an inability to mount an
efficient antigen-specific TD antibody response.
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Figure 5. Phenotype, repertoire and functionality of host-derived T cells in
lethally-irradiated BM chimeras. (A) Shown are CD44 and CD62L expression on gated CD4+
TCRβ+ (upper dot-plots) or CD8+TCRβ+ (lower dot-plots). Numbers in the quadrants indicate mean
percentages ± SD from at least 5 mice analysed per group. (B) Vb repertoire analysis among CD4+
and CD8+ T cells by FACS in chimeras. Each symbol represents a single mouse from control (),
NTX () or TX () group. Black bars represent mean value in control group. Ten mice per group were
analysed. (C) Depicted is T cell-dependent antibody responses in different group of chimeras day 14
after NIP-OVA immunization. Shown are relative titers of IgG anti-NIP specific antibodies. Each bar
represents a single mouse and 5-10 mice were analyzed. When the ratio [anti-NIP IgG titers after
immunization / anti-NIP IgG titers before immunization] was below 10 (horizontal line) we considered
that the mouse did not mount a T-dependent response. In control and NTX group, 5/5 mice made a
specific response with ratio >100. Among TX group, only 4/10 mice made a specific response
(hatched bars). Control, NTX or TX chimeras were the same as described in figure 2B.
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DISCUSSION
By carefully studying the kinetics of development, distribution, phenotype and
function of the host-derived T cells in BM chimeras, we have clarified their previously
unappreciated, but important, contribution to the restoration of the immune system.
We called this process “auto-reconstitution”. We revealed that following lethal
irradiation, host-derived haematopoietic cells in secondary lymphoid organs were
almost exclusively composed of T cells and totally devoid of B cells. In addition, host-
derived T cells represented a considerable proportion of total T cells (~5% of all T
cells six months post-BMT). Kinetic analysis showed that the proportion of host-
derived T cells decayed as donor-derived T cell development slowly took place in
B6B6 chimeras. In these competitive settings, where the donor BM generated T
cells, it was not possible to study host-derived T cells exclusively. Thus, we
generated non-competitive BM chimeras in which BM donor cells (either Rag2-/- or
CD3ε -/-) were incapable of generating T cells. Then, we were able for the first time to
quantify precisely host-derived T cells in these non-competitive chimeric settings.
Surprisingly, auto-reconstitution could generate a pool of T cells equivalent to 35%
that in normal mice. We could also show that T cell auto-reconstitution had two
origins: (i) a major, thymic-dependent pathway (Thy-D) and (ii) a minor, thymic-
independent pathway (Thy-I). Indeed, in CD3ε-/-B6 chimeras, by comparing host-
derived T cell numbers in euthymic (NTX) versus athymic (TX) hosts, we could
quantify Thy-D and Thy-I pathways. Thus, the Thy-D pathway accounted for 70% of
host-derived T cells, thereby representing the main source of host T cells in an auto-
reconstituted T cell compartment. This estimate is based on the assumption that the
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size of the Thy-I compartment is not drastically altered by the Thy-D cohort of T cells
and vice versa.
The Thy-D T cells were composed of the progeny of a single wave of T-cell
differentiation which reached a maximum 2 weeks following BMT. As host-derived
thymocyte differentiation is only transient and ceases around 3-4 weeks, the thymus
does not contain any DP cells later on and its cellularity decreases dramatically. This
has been previously characterized by others (Ceredig and MacDonald, 1982). The
Thy-D cohort of T cells provides a large number of naïve T cells with a diverse TCR
Vβ repertoire. Logically, this observation led us to investigate the nature of radio-
resistant thymocyte progenitors.
Recently, when addressing the cellular origin of the host-derived cohort of
thymocytes regenerating in BM chimeras, Maillard et al. (Maillard et al., 2006)
suggested that they arose from an abnormal sequence of differentiation starting from
a donor-derived CD25+ CD44- CD117- “DN3-like” stage and therefore might involve
an atypical thymocyte progenitor. In contrast, we could detect the presence of
genuine, or “conventional” CD25-/+ CD44+ CD117high DN1-2 cells. Such conventional
DN1-2 cells were few in number, representing around 2000 cells per mouse one
week post-BMT. Further analysis indicated that these T cell progenitors were mainly
(~95-99%) host-derived initially and were then replaced by donor derived progenitors
around 3 weeks post-BMT.
The toxicity of ionizing radiation to cells is associated with massive apoptosis
which is particularly acute in hematopoietic organs, well-known to be highly
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radiosensitive. Lethal γ-irradiation triggers DNA breaks which in turn activate DNA
repair mechanisms and/or p53-dependent apoptosis, unless DNA repair has been
carried out correctly (Jeggo and Lobrich, 2006; O'Driscoll and Jeggo, 2006). There is
a body of literature addressing the radio-sensitivity of lymphoid cells, but so far, there
are no clear mechanisms demonstrating why only some subpopulations of cells can
survive lethal irradiation damage. From in vitro experiments with cell lines, it has
been proposed that the cell cycle status at the time of irradiation might determine
their radio-sensitivity (Jeggo and Lobrich, 2006; Lobrich and Jeggo, 2007; Pawlik and
Keyomarsi, 2004). Thus, cycling cells harbour much more DNA alterations than their
quiescent counterparts and are more prone to die. This dogma by itself would hardly
explain what is going on in vivo in lethally irradiated mice. Indeed, it would seem that
memory T cells, which are known to be more rapidly cycling than their naïve
counterparts, survive whereas B cells, some of which are known to be more cycling
than others, are totally deleted. Thus, we believe that certain niches throughout the
body might provide lymphocytes with a particular environment with specific radio-
protective signals. In our study, the gut contained a higher proportion of radio-
resistant T cells and could be an interesting candidate for such a radio-protective
niche even though we cannot exclude a preferential relocalisation of surviving T cells
following total body irradiation (TBI). Interestingly, a role for the gut in radioprotection
was recently proposed because a polypeptide-drug derived from commensal
salmonella flagellin, which binds to Toll-like receptor 5 and which activates nuclear
factor-kB signalling, was able to prevent mice from gastrointestinal and hematopoietic
disorders following lethal TBI(Burdelya et al., 2008). Furthermore, in recipient mice
where the anti-apoptotic gene Bcl-2 was constitutively over-expressed (H2K-BCL-2
transgenic mouse), even host-derived B cells survived following TBI and BMT (data
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not shown and (Domen et al., 1998)). Thus, the clear contrast in survival properties of
B versus T cells might (at least partly) be due to intrinsic differences in their
expression of pro- versus anti-apoptotic genes. By intracellular staining, we have
already observed a higher baseline level of Bcl-2 expression in T cells versus B cells.
Clearly, the issue of the differential survival of T versus B cells following lethal
irradiation is warranted and might shed light on important pathways for
radioprotection at the cellular level.
As shown in TX recipients, the minor, Thy-I-derived, T cell component of auto-
reconstitution was composed of the progeny of mature, radio-resistant peripheral
CD4+ and CD8+ T cells. Following their survival and expansion post-irradiation, they
expressed a biased TCR Vβ repertoire. Phenotypically, these Thy-I cells had a
CD44High CD62L+/- memory-like phenotype which could correspond to their initial
phenotype or to a phenotype acquired upon lymphopenia-induced expansion (Bosco
et al., 2005; Bosco et al., 2006). Additionally, as we and others have previously
shown, these cells were enriched in FoxP-3+ regulatory T cells (Anderson et al.,
2004; Benard et al., 2006; Komatsu and Hori, 2007; Roord et al., 2008). Following
BMT in mice, these Thy-I Treg cells protected the host from GvHD complications in
syngeneic conditions (Benard et al., 2006). Others studies have shown that Treg, as
well as memory T cells, are more resistant to γ-irradiation, chemotherapy or antibody-
mediated depletion in vitro and in vivo (Anderson et al., 2004; Benard et al., 2006;
Bourgeois and Stockinger, 2006; Gladstone et al., 2007; Walzer et al., 2002). The
molecular mechanisms behind these interesting observations are still unknown and
require further experiments.
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Functionally, in NTX CD3ε-/-B6 thymus-bearing chimeras, host-derived CD4+
T cells alone were sufficient to mount a TD immune response whereas in TX
recipients, the immune response was frequently impaired. Clinically, it is
recommended that patients be re-vaccinated following BMT in order to restore a high
level of protection against many vaccine-preventable diseases such as measles,
tetanus, hepatitis or polio (Avigan et al., 2001; Gangappa et al., 2008; Ljungman et
al., 2005; Parkman, 2008; Patel et al., 2007). In this context, mouse BM chimeras
might provide a relevant experimental system to study immune response or diseases
associated with lymphopenia subsequent to conditioning regimens and BMT in
humans. Published observations suggested that host-derived cytomegalovirus-
specific (CMV) CD8+ memory T cells could provide efficient anti-viral immunity and
help patients survive the severe lymphopenic period following BMT (Chalandon et al.,
2006). However, studies in man are difficult to control experimentally and animal
models are required to dissect and improve the outcome of BMT.
In conclusion, our results demonstrate a so-far unappreciated, but important,
residual host-derived thymic activity following conditioning and BMT. These thymus-
derived T cells constitute a significant population of T cells with a polyclonal TCR Vβ
repertoire and normal functional properties. By analysing thymectomised recipients,
we could demonstrate that in their absence, lymphopenia was more severe, the T cell
repertoire was frequently oligoclonal and immune responses were compromised.
Therefore, strategies should be developed to improve and expand the Thy-D and/or
the Thy-I cohort of T cells which together could serve as a first line of defence in
lymphopenic hosts until donor-derived T cell reconstitution takes place. In this
regards, improving thymic reconstitution and peripheral T cell survival by, for
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example, infusing IL-7/anti-IL-7 complexes (Boyman et al., 2006; Boyman et al.,
2008) during thymus regeneration would appear to be a promising approach.
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MATERIALS & METHODS
Mice.
Female C57BL/6, C57BL/6.Rag2-/-, and C57BL/6.CD3ε-/- mice of either CD45.1 or
CD45.2 genotype were maintained in our SPF animal facility. As BM donors, mice
were used at 4-8 weeks of age and recipients were killed by CO2 inhalation prior to
analysis. These studies were approved by the institute animal care and user
committee.
Thymectomies.
At 4 to 6 weeks of age, mice were anesthetized and thymus was removed by suction
through a small upper sternal incision. That thymectomy had been complete was
verified in each animal by anatomical inspection at the time of sacrifice.
Cell preparation, immunofluorescence staining and FACS analysis.
Lymphoid organs (thymus, spleen or lymph nodes) were removed from adult
unmanipulated or chimeric mice at the indicated times. Single-cell suspensions were
generated by disruption of organs through a 40 µm nylon mesh via a syringe plunger
and were washed once with 2% FCS-supplemented DMEM. Spleen cell suspensions
were depleted of red cells by NH4Cl treatment prior to staining. Lymphocyte
suspensions from liver, lung and skin were prepared by standard procedures and
Percoll density gradient centrifugation performed as previously
described(Schleussner and Ceredig, 1993) prior to cell recovery. Biotin-, FITC-, PE-,
PE.Cy7-, or APC-conjugated mAbs were either home made or purchased from BD
Biosciences or eBioscience (San Diego, CA). Cell staining was performed as
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previously described (Bosco et al., 2005; Bosco et al., 2006) prior to FACS analysis
with a FACScalibur and CELLQuest Pro software (BD Bioscience). The data
presented are of live-gated cells based on a combination of forward- and side-scatter
signals and when possible propidium iodide exclusion.
Bone marrow transplantation.
Bone marrow cell suspensions from CD45 allogenic donor mice were prepared by
flushing femurs and tibias with PBS using a 23g needle. After a red blood cell lysis
step, T cells were depleted when necessary by resuspending cells in a mixture of rat
IgM anti-CD4 (RL172) and anti-CD8a (31M) mAb hybridoma supernatants and
incubated for 20 min at 4°C. Following a washing step, antibody-coated cells were
lysed by adding a 1:10 dilution of screened rabbit serum as source of complement in
serum free Dulbecco’s modified Eagle’s medium (DMEM) for 45 min at 37°C. Then,
cells were washed, resuspended in serum-free DMEM and counted prior to injection.
Host mice were lethally g-irradiated with a single dose of 950 cGy at a dose of 80 to
90 cGy/min using a Cobalt-source (Gammacell 40, Atomic energy of Canada, Ltd) 4h
prior to receiving 5x106 bone marrow cells intravenously. Chimeric mice were
analysed at the indicated time points and the host and donor origin of lymphoid cells
determined by means of labelled CD45.1- or CD45.2-specific mAbs.
Fetal thymic organ cultures
Fifteen day pregnant C57BL/6 mice were lethally irradiated (950 cGy) prior to embryo
removal. Thymus lobes from irradiated or control un-irradiated embryos were then
used for FTOC. For staining, lobes were dissociated by passing through needles of
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decreasing size as previously described (Balciunaite et al., 2005), washed in DMEM
medium and then stained and analyzed by flow cytometry.
Thymus DN preparation, cell sorting and culture on OP9-DL1 stroma.
From total thymocytes, CD4-CD8- double negative (DN) cells from control or chimeric
mice were prepared by complement-mediated lysis of CD4 and CD8 expressing
thymocytes as described above. DN thymocytes were then stained with combinations
of fluorescently-labelled CD25, CD44 and CD117 (c-kit) mAbs and pooled CD25-
DN1 and CD25+ DN2 cells sorted as CD117highCD44+ cells using a FACSAria sorter
(BD Biosciences). Reanalysis of sorted cells indicated that their purity was routinely ≥
98%.
OP9 stromal cells expressing the Notch ligand delta-like-1 (OP9-DL1) were kindly
provided by Professor Juan-Carlos Zúñiga-Pflücker (University of Toronto, ON,
Canada) and maintained in IMDM supplemented with 5 x 10–5 M -mercaptoethanol,
1 mM glutamine, 0.03% (wt/vol) Primatone (Quest, Naarden, The Netherlands), 100
U/mL penicillin, 100 µg/mL streptomycin, and 2% heat-inactivated fetal bovine serum
(FBS). Two days prior to coculture, 104 stromal cells were seeded per well of a 24-
well plate. At day 0, stromal cells had grown to semi-confluency and were then -
irradiated with 3000 cGy, culture medium removed and replaced by supplemented
DMEM plus IL-7 (~10ng/mL). To these cultures were added ~5x103 sorted DN1 and
DN2 thymocytes. At day 10-14 of culture, cells were either analysed by FCM or kept
in culture after transfer to fresh OP9-DL1 stromal cells.
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T cell-dependent antibody responses.
To induce a T cell-dependent antibody response, reconstituted chimeric mice were
injected subcutanously with 200µl complete Freund’s adjuvant emulsion containing
50 µg total NIP-ovalbumin. Sera were obtained after bleeding prior to and 14 days
after immunization and stored at –20°C. Hapten-specific IgG antibody titres were
determined by enzyme-linked immunosorbent assay (ELISA) as previously described
(Ceredig et al., 2006).
Immunofluoresecent staining of spleen sections.
Spleens were snap frozen with dry ice in Tissue-Tek OCT compound and then 5 to 7-
µm sections cut on a cryostat. Sections were then fixed for 10 min in acetone and
stored at -80°C. For staining, sections were covered with an antibody solution at
saturating concentration diluted in PBS-1% FBS for 1h at room temperature. Anti-
B220Biotin and anti-CD90FITC were used to discriminate B and T cell areas
respectively, and PNABiotin (Peanut Agglutinin, Vector Laboratories) and anti-IgMFITC
(M41) used to reveal germinal centres (GC). For the second step, sections were
washed in PBS (three times 10 min) and incubated 30 min at room temperature with
a Neutralite Avidin-Texas-Red reagent (Southern Biotech) diluted in PBS. Then,
sections were washed, coverslipped and analyzed under a fluorescence microscope
(Zeiss axioskope) with a 10 to 20x objective.
Statistical analyses.
Data are presented as the mean and SEM. Comparisons between groups were done
using a Student’s two-tailed t test for independent events. P values of less than 0.05
were considered significant (, p value <0.05 and , p value <0.01).
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7. General discussion 
 
In this work we have investigated several aspects T cell central and peripheral 
tolerance, I would like now to compare and contrast two different experiments 
related to the treatment of autoimmune and GvH diseases.  
In the first study, we demonstrated the CD11c-HA x TCR-HA double 
transgenic mice could be partially rescued from premature death by transfer 
of HA-specific Treg whereas treatment failed to prevent overall signs of 
autoimmunity.  
In the second study, we could show that the treatment of BDF1 mice with 
FLT3L prior to GvHD induction was able to rescue as much as 100% of the 
mice and that no other major signs of disease could be observed 
(summarized in table 1). 
 
Model Disease Treatment Survival upon 
treatment 
CD11c-HA x 
TCR-HA 
Systemic 
autoimmunity 
Injection of sorted HA-
specific Treg 
Partial rescue 
B6 -> BDF1 Acute GvH 
disease 
Semi-therapeutic 
FLT3L injections 
Complete rescue 
 
Table 1. Treatment of autoimmune and GvH diseases.  
Even though, these two systems are completely different in both case CD4 T 
cells play an instrumental role in the development of the disease and the 
establishment of T cell tolerance seems to be a key point in the success of the 
therapy. We can hypothesize on why the first treatment failed to prevent 
disease whereas the second seems to be very efficient in this regard.  
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Chronic vs acute disease 
A major difference between the two models is that in CD11c-HA x TCR-HA 
mice, auto-reactive T cells are constantly produced by the thymus whereas 
GvHD is induced by injection of a fixed number of alloreactive T cells. In the 
latter situation the resulting disease has a more acute form.  
In other words, the success of the treatment of CD11c-HA x TCR HA depends 
on long-term establishment of tolerance because self-reactive T cells are 
always exported. In contrast, the control and/or deletion of fixed number of 
alloreactive T cells might be sufficient to prevent GvHD. As already discussed, 
chronic defects in central tolerance might be difficult to cure, this could be an 
explanation why autoimmunity in CD11c-HA x TCR-HA is difficult to treat. 
 
Cellular vs cytokine therapy 
An obvious limitation of cellular therapy, e.g. transfer of Treg cells, is the 
restricted survival and migration of injected cells. Unfortunately we did not 
monitor the fate of donor cells and we have no data regarding these issues 
however we can speculate that a majority of injected cells might die because 
of lack of survival signals and/or inability to migrate in lymphoid organs. We 
do not know either whether Treg can persist in the constant presence of their 
cognate antigen or whether cells get exhausted similarly to effector cells. 
Altogether, the limited number of cells and their long-term survival is a clear 
problem in the treatment of chronic disease.  
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In contrast, FLT3L treatment induces expansion of DC and Treg compartment 
in situ. The treatment is therefore much more efficient because cells expand 
in their physiological environment where survival signals are provided and 
where they can deliver they tolerogenic function.  
Therefore considering “Treg therapy”, expansion of pre-existing cells (with 
relevant specificity) is probably a better approach than transfer. FLT3L is a 
highly potent cytokine to increase the number of DC and we have shown here 
that it expands peripheral Treg compartment. However it is doing so in a 
rather inefficient manner regarding the amount of cytokine needed compared 
to the expansion. Other ways of expanding Treg in vivo have been published 
among which injection of IL-2/anti-IL-2 complexes seems to be particularly 
efficient 70. Authors could actually demonstrate that such treatment could 
prevent spontaneous diabetes in NOD mice. It is important to notice here that 
treatment by complexes is expanding Treg to a level that is probably 
impossible to achieve by transfer of cells.  
 
Treg vs DC therapy 
In the first study, the treatment is based on transfer of HA-specific Treg cells 
whereas in the second, the strategy was to expand DC and Treg 
compartment by repetitive injection of FLT3L. We are currently trying to 
dissect the role of DC and Treg in therapeutic effect of FLT3L however, given 
the respective expansion of both compartment we hypothesized that most of 
the therapeutic effect is DC-mediated.  
In other words, we can speak here about Treg- versus DC-mediated therapy. 
As already mentioned, it is not fair to compare both therapies because models 
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are different and unfortunately we could not apply these two therapies on the 
same model. However conceptually, we can make a contrast between a 
“repressor” versus an “educational” strategy. The goal of Treg therapy is to 
control self-reactive T cells, to “repress” whereas the objective of DC therapy 
is to differentiate allo/self-reactive T cell toward an anergic or regulatory 
phenotype, to “educate” T cells and/or eventually to delete them. This makes 
DC-mediated therapy more interesting at least in theory.  
 
Clinical applications 
One last point of comparison is the potential application of such therapies to 
human. Cellular therapy like Treg transfer seems to be highly difficult to 
achieve, because it needs to manipulate cells from the patient ex-vivo e.g. 
convert Ag-specific T cells toward regulatory phenotype in order to re-inject 
them in the patient. Such protocols have tremendous costs in time and money 
and require extreme cautions due to the ex-vivo manipulation of the cells. In 
contrast, treatment of patients with recombinant cytokines is much more 
simple.  
For these reasons, cytokine-mediated expansion of Treg or DC are probably 
much more interesting in clinical perspective. 
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